
==== Front
Curr Neuropharmacol
Curr Neuropharmacol
CN
Current Neuropharmacology
1570-159X
1875-6190
Bentham Science Publishers

38504566
CN-22-1826
10.2174/1570159X22666240319123151
Medicine, Neurology, Pharmacology, Neuroscience
Histaminergic System and Vestibular Function in Normal and Pathological Conditions
Tighilet Brahim 1*
Trico Jessica 1
Marouane Emna 12
Zwergal Andreas 34
Chabbert Christian 1
1 Aix Marseille Université-CNRS, Laboratoire de Neurosciences Cognitives, LNC UMR 7291, Marseille, Groupe de Recherche Vertige (GDR#2074), France;
2 Normandie Université, UNICAEN, INSERM, COMETE, CYCERON, CHU Caen, 14000, Caen, France;
3 Department of Neurology, LMU University Hospital, Munich, Germany;
4 German Center for Vertigo and Balance Disorders, LMU University Hospital, Munich, Germany
* Address correspondence to this author at the Aix Marseille Université-CNRS, Laboratoire de Neurosciences Cognitives, LNC UMR 7291, Marseille, France, Groupe de Recherche Vertige (GDR#2074); Fax: +33413550869; E-mail: brahim.tighilet@univ-amu.fr
19 3 2024
2024
22 11 18261845
13 6 2023
20 9 2023
13 10 2023
© 2024 The Author(s). Published by Bentham Science Publishers
2024
The Author(s)
https://creativecommons.org/licenses/by/4.0/ © 2024 The Author(s). Published by Bentham Science Publishers. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode.
Most neurotransmitter systems are represented in the central and peripheral vestibular system and are thereby involved both in normal vestibular signal processing and the pathophysiology of vestibular disorders. However, there is a special relationship between the vestibular system and the histaminergic system. The purpose of this review is to document how the histaminergic system interferes with normal and pathological vestibular function. In particular, we will discuss neurobiological mechanisms such as neuroinflammation that involve histamine to modulate and allow restoration of balance function in the situation of a vestibular insult. These adaptive mechanisms represent targets of histaminergic pharmacological compounds capable of restoring vestibular function in pathological situations. The clinical use of drugs targeting the histaminergic system in various vestibular disorders is critically discussed.

Keywords

Vestibular system
histaminergic system
vestibular disorders
neuroinflammation
histaminergic drugs
vertigo
==== Body
pmc1 INTRODUCTION

1.1 Anatomical and Functional Organization of the Vestibular System

To maintain body's balance, the central nervous system uses visual, proprioceptive, tactile and above all, vestibular information. Vestibular inputs are detected by specific sensors located in the inner ear close to the cochlea. The vestibular sensors in each inner ear are organized in three cristae ampullaris and the two otolithic organs, the saccule and the utricle [1]. The crista ampullaris detects the accelerations resulting from angular movements, while the otolithic organs detect the accelerations resulting from linear movements of the head and gravitational accelerations. The sensory inputs generated by the vestibular sensors are conveyed through the vestibular nerve towards the first central nervous relay: the brainstem vestibular nuclei complex (VNC). This nuclear complex consists of four different vestibular nuclei (VN): the median vestibular nuclei (MVN), the inferior vestibular nuclei (IVN), the lateral vestibular nuclei (LVN) and the superior vestibular nuclei (SVN). The VNs are located in the dorsolateral part of the pontomedullary junction of the brainstem, under the floor of the fourth ventricle. The vestibular sensory information reaching the VN level is then integrated and converted into a specific motor message dedicated to the regulation and control of postural, locomotor balance and oculomotor function [2]. Hence this sensorimotor system designation is attributed exclusively to the vestibular system. The vestibulo-ocular reflex (VOR) intends essentially for stabilizing the gaze during head movements, and the vestibulo-spinal reflex (VSR) directs readjustments and stabilization of the head and body in static (standing) and dynamic (walking) conditions. These compensatory vestibular reflexes are exerted at the level of the extrinsic musculature of the eye through the vestibulo-ocular reflex, as well as at the level of the neck and trunk axial musculature, and limbs proximo-distal musculature through the vestibulo-spinal reflexes (Fig. 1).

A particularity of this integrating nerve center is that the VNs receive a multitude of information from other sensory modalities such as vision, proprioception, touch and to a lesser degree hearing [3-7]. The vestibular system is also involved in perceptual and cognitive functions supported by cortical areas involved in the processing of peripheral vestibular inputs. Among these areas, well documented in the literature, the parieto-insular vestibular cortex is the most representative [8-11]. This multisensory area manages functions such as perception of verticality, representation of the body scheme and orientation of body in space [11-13]. The vestibular system also sends information to important nervous structures such as the hippocampus, the hypothalamus, the amygdala, the ventral tegmental area [14-19]. This is why VNs were recently referred as a “hub” linked to several networked nervous structures, receiving, organizing, and redirecting the sensory inputs to multiple functional targets [6, 20].

1.2 Unilateral Peripheral Vestibular Syndrome and its Compensation

In human and most species, acute unilateral vestibular loss induces static and dynamic vestibular signs and symptoms consisting of vestibulo-ocular (nystagmus, cyclotorsion, altered vestibulo ocular reflex generating oscillopsia), posturo-locomotor (postural instability, falls, ipsilateral deviation from the walking path), vegetative (nausea, vomiting, salivation) and perceptive-cognitive (spatial disorientation, vertigo) deficits. These static and dynamic deficits compensate differently, either partially or completely and with different time course. This spontaneous post-lesional functional recovery is referred in the literature as “central vestibular compensation” (Fig. 2) [21-23]. The static deficits (those present in absence of body movements) compensate for the most part. It is now well established that static deficits result from the imbalance of spontaneous resting activity between the ipsi- and contralesional VNs. Compensation approximately coincides with restoration of balanced electrical activity between VNCs. These events were confirmed electrophysiologically in many studies [24-26]. The dynamic deficits (those present during body movements) are not completely compensated and present for a longer time. Recovery of dynamic deficits seems not to depend on rebalanced activity in the VNs solely, but is attributed to multiple plasticity mechanisms occurring in various brain areas [21, 23, 27-35].

2 HISTAMINE AND VESTIBULAR FUNCTION

A large variety of neurotransmitters is present in the vestibular system. However, histamine occupies a peculiar position in vestibular physiology due to the expression of all histamine receptors (HR) in the vestibular sensory network. Histamine is also involved in regulating both the normal response to vestibular stimulation and the reactive processes that support vestibular compensation. Pharmacological modulation of histamine production and release has been proven to enhance functional recovery in vestibular animal models [36-38] and patients with vestibular disorders [39]. Thus, histamine receptors seem suitable targets for modulating vestibular sensory information.

2.1 Brain Source of Histamine

Histamine is synthesized from the amino acid L-histidine by the enzyme histidine decarboxylase and the main pathway of histamine degradation is based on the action of histamine N-methyltransferase followed by monoamine oxidase B [40] (Fig. 3a). Brain sources of histamine include mast cells, neurons and microglia [40-42]. In the adult mammalian brain, the histaminergic neurons are exclusively located in the tuberomammillary nucleus of the posterior hypothalamus (TMN) from where they project their fibers and terminals to the whole brain including VNs (Fig. 3b) [40, 43-46].

2.2 Brain Distribution of Histamine Receptors

Histaminergic receptors are widely found in the central nervous system.

Histamine type 1 receptor (H1R) exhibits a wide distribution in the central nervous system, particularly in brain areas involved in arousal, including the thalamus, cortex, cholinergic nuclei, locus coeruleus and raphe nuclei [40, 47, 48]. These findings have been ascertained through binding assays [49] and RT-PCR techniques [50] in rat models, autoradiography in ginea pigs [51] and in situ hybridation and receptor binding autoradiography [52], or PET-scan imaging [53] in human samples. Moreover, H1R has been located in the limbic system (i.e. several nuclei of the hypothalamus, medial amygdala and hippocampus) [40, 47] using binding assay techniques across diverse mammalian species [48, 54]. Receptor autoradiography techniques carried out on both human and non-human primate samples [55], alongside human PET-scan imaging [53], have consistently revealed the presence of H1R in the limbic system. Additionally, H1R is detectable in the cerebellum [53] and basal ganglia [55]. Nevertheless, it is worth knowing that interspecies variations exist [48, 54].

Given that both H1R and H2R are present in the same cerebral regions, an overlapping of their functions in behavior has been established [56]. H2R, akin to H1R, is localized in the hippocampus, amygdala, basal ganglia and cerebral cortex [40, 43]. These findings have been corroborated through several techniques, including in situ hybridization techniques in rat models [57], radioligand binding and in situ hybridization techniques in ginea pigs [58], as well as receptor binding autoradiography [55, 59] and in situ hybridization techniques [52] in non-human primates and humans samples. Finally, H2R is also localized in the cerebellum and hypothalamus [59].

H3R shares common localization with H1R and H2R. High-density expression of H3R is observed in the basal ganglia (i.e. striatum and substantia nigra), as well as the hippocampus [40, 47, 60]. These localizations have been ascertained through various techniques applied in rodent models, such as immunohistochemistry [61], receptor binding autoradiography [62] and in situ hybridization [63]. In human and non-human primate studies, H3R has been found in the basal ganglia using in situ hybridization and receptor binding techniques [64] while its presence in the hippocampus has been established using autoradiography [55]. Additionally, H3R has also been identified in the hypothalamus, thalamus and cortex [40, 52, 60, 61].

H4R has been localized in various regions of the rat central nervous system, including the cortex, cerebellum, brainstem, amygdala, thalamus and striatum [65]. Furthermore, H4R has been detected in human samples within the hippocampus, cortex, thalamus and amygdala [65, 66]. It is noteworthy that discrepancies in the distribution of H4R within the brain exist among different species [65] and the expression and function of H4R in the central nervous system remains controversial and requires further investigation [67].

2.3 Expression of Histaminergic Receptors in the Vestibular System

The different types of histaminergic receptors are expressed at the levels of central and peripheral vestibular systems. At the central level (Fig. 4a), the VNs contain three types of histamine receptors (H1R, H2R and H3R), as shown using ligand-binding [51, 58, 68, 69], in situ hybridization methods [58, 63, 70], or in immunohistochemistry [36]. H1R and H2R are located in a post-synaptic position in vestibular neurons, whereas H3R is located in a pre-synaptic position on histaminergic afferents from neurons of the posterior hypothalamus [62]. In this situation, H3R acts as an autoreceptor which regulates the synthesis and release of histamine. In addition, H3R can also be found on non-histaminergic afferents and is then considered as a heteroreceptor that modulates the regulation and synthesis of other neurotransmitters. Finally, as H4R is expressed on microglia, known to be present in VNs, the presence of H4R in VNs is highly probable (this aspect is developed in section 4). These aspects confer a neuromodulatory role to histamine in the brain.

In the peripheral labyrinth (Fig. 4b), the four types of histamine receptors (H1R, H2R, H3R and H4R) have been located in both hair cells and vestibular primary neurons [71-74]. Using an RT-PCR approach, Takumida and colleagues recently revealed that the different types of histamine receptors are expressed in different proportions depending on the cell type considered. Vestibular hair cells are classified into two categories, distinguished by their morphology (bottle-shaped for type I vestibular hair cells and more cylindrical for type II vestibular hair cells), their ion channel equipment (gK,L current is specific to type I vestibular hair cells) as well as their afferentation by vestibular nerve fibers (calyx endings are found exclusively on type I vestibular hair cells) [75]. According to Møller et al. combined microarrays and immunohistochemistry approaches showed expression of the H1R in the epithelial lining of the endolymphatic sac, while H3R are expressed exclusively in the subepithelial capillary network. H2R and H4R were not found in the endolymphatic sac [76].

2.4 Function of the Histamine Receptors in the Vestibular System

Despite ongoing research efforts, the physiological relevance of histamine receptors expression in the vestibular system remains unclear and requires further investigation.

At the peripheral level, it is known for almost fifty years that the antagonization of H1R (i.e., pyrilamine, diphenhydramine) significantly alters the vestibular primary neuron excitability in a dose dependent manner [77]. Similarly, H3R antagonists (i.e., thioperamide, clobenpropit and betahistine) decrease the electrical discharge of primary vestibular neurons [78] and betahistine could reduce resting activation rate of peripheral vestibular sensors [79].

At central level, in vitro extracellular and intracellular recordings in IVN, SVN, MVN and LVN neurons revealed histamine induced depolarization through postsynaptic H1R and H2R [80-86]. These findings attest that histamine has an excitatory action in the VNs.

Vestibular stimulations of rotatory [87], electric and caloric [88], or gravitational [89] nature commonly increase histamine release in the hypothalamus and brainstem. Local perfusion of the VN on one side with H2R antagonists or H3R agonists induces a stereotyped postural and oculomotor syndrome in the guinea pig that mimics that observed after labyrinthectomy [90].

Given the presence of histaminergic receptors throughout the peripheral and central vestibular system and their proven involvement in vestibular signal processing, there is a high likelihood that histamine also plays a significant role in vestibular compensation.

3 HISTAMINE AND VESTIBULAR COMPENSATION

A direct link between vestibular compensation and increased histamine turnover has been established in the central nervous system of adult cats [37, 38, 69, 91, 92]. Unilateral section of the vestibular nerve induces a spontaneous electrical activity imbalance between the bilateral vestibular VNs with hyperactivity on the intact side and hypoactivity on the deafferented side. This electrophysiological imbalance induces an activation of histaminergic tuberomammillary neurons of the posterior hypothalamus via vestibulo-hypothalamic loops [93] which results both in a local increase of the histamine synthesis and its release in the VNs (Fig. 5). These mechanisms are prevented upon bilateral vestibular neurectomy [69]. This confirms that the electrophysiological asymmetry between the intact and deafferented VN is the cause of the histaminergic system activation. The elevated histamine release may participate in rebalancing the spontaneous activity between the bilateral VNs, a key parameter of the vestibular compensation, by its depolarizing effect on H1R and H2R (Fig. 5). Furthermore, altered histamine levels after a vestibular injury may have effects on various vestibular plasticity mechanisms, such as neuroinflammation.

4 EFFECT OF HISTAMINE ON NEUROINFLAMMATION IN VESTIBULAR DISORDERS

Inflammation is a multi-faced process which involves complex cellular and molecular mechanisms triggered by stress, injury, or infection, with the ultimate goal of returning to physiological homeostasis. In the central nervous system, inflammation is known as neuroinflammation and is characterized by the involvement of two key players: microglial cells and astrocytes, which, under physiological conditions, contribute to the central nervous system homeostasis.

4.1 Neuroinflammation in Acute Peripheral Vestibulopathy

Acute unilateral vestibulopathy (AUVP; vestibular neuritis), characterized by vertigo/dizziness, spontaneous nystagmus, postural imbalance and vegetative symptoms, has been associated with the presence of local and systemic inflammation in affected patients [94, 95]. Although its etiology is still debated (viral, vascular, inflammatory), inflammation of the vestibular afferents (labyrinth/vestibular nerve) is one of the proposed causes [96] and has led to the administration of corticosteroids as a treatment principle [97]. While data from clinical trials suggest some effect of early administration of corticosteroids on the recovery of peripheral vestibular function on the longer term [98], its benefit for vestibular compensation is questioned by recent meta-analyses [97, 99-101]. Accordingly, there is consensus that further drug research is needed to better control the acute symptoms of patients with AUVP.

4.2 Neuroinflammation in Animal Models of Acute Peripheral Vestibulopathy

Some animal models of vestibular loss generate an inflammatory response in the central nervous structures which process vestibular information. Postganglionic damage to vestibular afferents by unilateral vestibular neurectomy (UVN) results in the recruitment of astrocytes [102-105] and microglia [104, 105] in the ipsilesional VNs. Given its ability to consistently reproduce the typical behavioral phenotype of AUVP, the UVN model is particularly relevant to study the role of central inflammation in vestibular pathophysiology and to investigate how pharmacological modulation of inflammation can affect the expression of this pathology. Other models of vestibulopathies are known to generate central vestibular inflammation, such as the surgical labyrinthine destruction model [103, 106-108] or chemical model using arsanilate [109]. Transtympanic injection of arsanilate irreversibly desensitizes the vestibular sensors of the inner ear [110]. This chemical vestibular lesion model induces the expression of two key inflammatory factors, the tumor necrosis factor-alpha (TNF-α) and the nuclear factor-kappa B (NF-kB) in the deafferented VNs [109]. Furthermore, this model elicits both a peripheral (vestibular nerve) and central (VNC) inflammatory response [111]. Thus, all these models are appropriate to study the impact of neuroinflammatory processes in vestibular core hubs. The interest in understanding the role of inflammatory processes correlated with vestibular pathologies goes well beyond the vestibular models mentioned above since pro-inflammatory signatures have also been recently reported in Menière's disease and vestibular migraine [112].

4.3 The Dual Role of Histamine in Neuroinflammation

Astrocytes and microglial cells are crucial components of the glial inflammatory response in the central nervous system [113]. These cells express histamine receptors [114, 115] and microglial cells produce histamine [41]. The idea that histamine would play a role in inflammation has thus encouraged much research. Xu and al. demonstrated that histamine inhibits the production of the pro-inflammatory cytokine TNF-α and interleukin 1 beta (IL-1β) in a concentration-dependent manner in astrocytes. In addition, a knockout mouse model of the histamine-synthesizing enzyme, histidine decarboxylase, led to a decrease in microglial arborization [116]. Thus, there is a strong link between histamine and inflammation, but this link is complex. Multiple studies have demonstrated the dual role of histamine in modulating inflammation depending on the microenvironment [117, 118].

In vitro and in vivo histaminergic stimulation of H1R and H4R results in the activation of microglia, which then secretes proinflammatory factors such as TNF-α, interleukin 6 (IL-6), IL-1β, prostaglandin E2 and reactive oxygen species (ROS) [114, 119-122]. Furthermore, activation of H1R also elicits an increase in phagocytic activity [120]. The proinflammatory response elicited by histamine administration can result in neuronal damage and even neuronal degeneration, both in vitro and in vivo [120, 123].

Contrary to its proinflammatory effect in a physiological context, histamine has been demonstrated to possess anti-inflammatory properties in an inflammatory micro-environment (Fig. 6). The anti-inflammatory action of histamine is primarily mediated by H2R and H3R, which trigger the release of anti-inflammatory cytokines such as interleukin 10 (IL-10) [121, 124, 125]. In vitro studies have shown that histaminergic stimulation of H2R suppresses inflammation induced by lipopolysaccharide (LPS) injection in human monocytes by decreasing TNF-α secretion [126] and cluster of differentiation 14 (CD14) expression [127]. Similar effects have been observed in human monocyte-derived dendritic cells and immune cells, where histamine increased the production of anti-inflammatory cytokines (IL-4), reduced the production of pro-inflammatory factors (TNF-α, d’IFN-γ) and led to cytoskeleton rearrangements [128]. Additionally, after LPS injection, histamine modulated microglial cells in vitro by reducing migration and IL-1β release [118] and dose-dependently inhibited phagocytosis and cytokine production (TNF-α) through H3R activation [129]. The anti-inflammatory effects of histamine have also been established in vivo, where it has been showed to inhibit phagocytic activity and ROS production, contributing to a neuroprotective effect [117]. The relationship between the histaminergic system and neuroinflammation is thus robust and underscores the neuroprotective nature of histamine in an inflammatory context.

4.4 Neuroinflammation and Vestibular Compensation

Microglial and astrocytic responses are expressed at their peak during the acute phase of the vestibular syndrome and then gradually decrease over time, but persist during the chronic phase [103, 105, 106, 108, 130]. A recent longitudinal study utilizing advanced imaging and tracing techniques has revealed that a vestibular lesion activates microglia in the vestibular nerve and brainstem nuclei [111]. Thus, a vestibular lesion induces an inflammatory context in the VNs that plays a crucial role in vestibular compensation and functional recovery. There is a delicate balance between inflammation and vestibular compensation, since an anti-inflammatory treatment during the acute phase of the vestibular syndrome delays both vestibular compensation and adaptive plasticity [131]. However, the relationship between inflammation and vestibular compensation is complex. Indeed, sensorimotor rehabilitation [132] and pharmacological treatments such as L-thyroxine [133] or betahistine (unpublished data) have been shown to increase the differentiation and survival of microglial cells at the expense of neurons, and reduce significantly posturo-locomotor deficits in an animal model of vestibulopathy. This surprising result, in view of the demonstration of functional reactive neurogenesis after vestibular injury [102, 105], could be explained by a microglial anti-inflammatory neuroprotective action, conferred by the effective rehabilitation or pharmacological treatment used. Moreover, a preliminary study has shown differential expression dynamics of microglial phenotypes during vestibular compensation [134]. Further studies on the amount of pro- or anti-inflammatory cytokines in these contexts are thus interesting. In betahistine-treated UVN animals, this anti-inflammatory effect may be mediated by H3R blockade, leading to activation of the cAMP/PKA/CREB pathway and the inhibition of glial-mediated inflammation [135]. This hypothesis is supported by the observation that histamine prevents the reduction of CREB protein levels only in an inflammatory context [136]. Thus, elevated histamine levels may promote differentiation towards a microglial phenotype with a neuroprotective role in a neuroinflammatory context triggered by vestibular injury. This neuroprotective phenotype could help to reduce the number of dying neurons, thus avoiding the cost of neuronal differentiation to the organism (Fig. 7). Further studies on the rate of apoptosis and cytokine levels in VN as a function of rehabilitation or pharmacological therapy would be of great interest. The central role of inflammation in vestibular disorders is further supported by a recent study in Menière’s disease patients, where elevated levels of IL-1β and TNF-α were observed [137]. All these data highlight a modulation of vestibular functions by central histaminergic system and suggest potential targets for clinical treatment of vestibular disorders.

5 HISTAMINE RECEPTORS MODULATORS AND PHARMACOTHERAPY OF VESTIBULAR DISORDERS

5.1 Differential Applications of Histaminergic Drugs in Various Vestibular Disorders

The pharmacotherapy of the vestibular system is relatively well documented [72, 138, 139], but an effective treatment for the diverse symptoms of vestibular syndromes remains to be found. Histamine receptor modulation holds a central place in drug research on vestibular disorders, given the abundant expression of HRs across the peripheral and central vestibular networks. Modulators of the H1R and H3R are among the drugs most commonly used in the treatment of vestibular disorders [72, 140-142], while H4R modulators are under development in this field [71, 143]. From a conceptual perspective, HR modulators could be helpful in the following clinical scenarios, each of which require a slightly different mode of action based on the underlying pathophysiological mechanisms: 1) application as an antivertigo drug in episodes of vestibular imbalance by suppression of peripheral or central vestibular tone asymmetry, 2) reduction of attack frequency and duration in hydroptic ear disease (including Menière’s disease) by action on fluid homeostasis in the inner ear, 3) use for augmentation of central vestibular compensation following AUVP by modulation of adaptive neuroplasticity mechanism.

5.2 Treatments Based on Histamine Receptor Type 1 Antagonization (Antivertigo Drugs)

Besides betahistine, there are a few drugs in clinical use for symptom control in vestibular disorders, which convey at least some of their therapeutic effects by antagonism to histamine receptors:

Dimenhydrinate predominently acts via antagonism to the H1R and muscarinergic acetylcholine receptor (mAChR): [144, 145]. Functionally, dimenhydrinate suppresses spontaneous as well as stimulation-induced firing of neurons in the vestibular nuclei [146]. It is considered as a vestibuar suppressant and frequently used for the symptomatic treatment of nausea and vomiting in acute episodes of vertigo or dizziness or the prevention of motion sickness.

Meclizine and cyclizine are antagonists at H1R, but in addition have anticholinergic effects. They are in use in the United States for the treatment of nausea, vomiting in vestibular disorders and motion sickness. Their antiemetic and antivertigo effects are not fully understood, but its central antihistaminergic and anticholinergic properties are likely involved. The drugs depress labyrinth excitability and vestibular stimulation and may affect the medullary chemoreceptor trigger zone.

Cinnarizine has multiple actions, including blockage of L-/T-type voltage-gated calcium channels and antagonism to the H1R [147]. It is also used for symptomatic treatment of vertigo, nausea, vomiting and motion sickness in clinical practice. Cinnarizine acts as a vestibular suppressant mostly on peripheral vestibular structures by inhibition of Ca2+ ion translocation across cell membranes of the vestibular sensory cells in the ampullae [148], by modulation of transmitter release in vestibular hair cells [149], and potentially also by anti-vasoconstrictive action in the stria vascularis [150]. Some binding of cinnarizine to voltage-gated calcium channels in the cerebral cortex has been reported [151]. Convincing experimental data for a direct receptor-mediated central action at the level of the vestibular nuclei is however missing [152].

Cinnarizine is also available in fixed combination with dimenhydrinate in various countries for the indications vertigo, nausea and vomiting in acute and episodic vestibular disorders [153-155]. In a prospective study, cinnarizine/dimenhydrinate (20 mg/40 mg) showed a non-inferiority to betahistine (16 mg) for symptomatic treatment of vertigo in patients with peripheral vestibular disorders [156, 157]. Observational studies also suggest an effect of either cinnarizine or cinnarizine/dimenhydrinate for attack reduction in vestibular migraine [158, 159].

Flunarizine is a first-generation antihistaminergic drug, which acts as an antagonist to the H1R. In addition, it is a selective calcium entry blocker with calmodulin binding properties. Thus, it has pharmacological similarities to cinnarizine. Main indications in vestibular medicine are the symptomatic treatment of peripheral and central vertigo [160] as well as vestibular migraine [161, 162].

In summary, vestibular suppressants such as the first-generation anihistaminergic durgs dimenhydrinate, meclizine, cyclizine, cinnarizine or flunarizine have a reverse binding pattern to H1R compared to betahistine. In consequence, the major difference of their action may be that the H1R antagonists suppress symptoms, while having the risk to delay mechanisms of central vestibular plasticity after unilateral peripheral vestibular loss. In contrast, betahistine does have less acute symptomatic effects, but a positive action for adaptive vestibular neuroplasticity (developped in section 5.5). Further, H1R antagonists but not the H1R agonist betahistine tend to have sedative side effects such as drowsiness.

5.3 Treatments Based on Histamine Receptor in the Inner Ear (Hydroptic Ear Disease)

In terms of the pharmacological treatment of Menière disease, betahistine has remained the most widely used drug in Europe for several decades [72, 140, 163, 164]. Experimental data from animal models give a strong rationale for a positive action of betahistine in the inner ear. At the peripheral vascular system level, betahistine has been shown to increase cochlear and vestibular blood flows, improving the inner ear microcirculation [165-168]. This effect is believed to be mediated by histamine H3 heteroreceptors and H1 receptors [169-172] which could alleviate the microcirculation impairments and decrease the endolymphatic hydrops accompanying Menière’s disease [165, 170].

Nevertheless, the clinical literature differs on the betahistine efficacy [173]. No effect of betahistine treatment has been found at low or high dose in Menière’s disease patients in a double blind, randomized and placebo controlled trial [174], while others studies found positive effect of betahistine treatment in vestibular disorders [39, 175-179]. There is a need for more thorough research on the effectiveness of betahistine in patients suffering from Menière’s disease [180]. Future studies should use the consented diagnostic criteria, select drug formulations, which take the specific metabolism of betahistine into account, always include a control group, and apply meaningful patient-oriented outcome measures.

5.4 Treatments Based on Augmentation of Vestibular Compensation by Histamine Receptor Modulation (AUVP)

Preclinical research on the use of betahistine in animal models of acute unilateral vestibular deafferentation is limited. The few reported works show a beneficial action of an oral treatment with betahistine on the acute vestibular syndrome in a cat [37, 38, 181] and rodent UVN model (unpublished data). Another study highlights that the faster recovery in posturo-locomotor symptoms in cats following UVN occurs in conjunction with elevated plasma concentrations of betahistine and an upregulation of histidine decarboxylase in the hypothalamus [38]. In the rodent model of surgical labyrinthectomy, either microinjection of betahistine in MVNs, intragastric infusion of betahistine or continuous administration through an osmotic minipump had beneficial effects on the restauration of vestibular functions [36, 182, 183]. In a chemical labyrinthectomy rat model, betahistine had dose-dependent beneficial effects on postural imbalance and mobility (Antons et al., 2023). Surgical vestibulopathy models, such as UVN and labyrinthectomy, as well as the unilateral intratympanic gentamycin application model [184] are comparable as they all lead to similar vestibular symptoms [185]. These lesions induce a vestibular syndrome similar to AUVP encountered in the clinic, characterized by sudden onset of vertigo or dizziness, accompanied by nausea and vomiting, gait instability, head motion intolerance and nystagmus, which persist over at least a day. Besides the sporadic cases of AUVP (i.e., vestibular neuritis), surgical or chemical damage to the peripheral vestibular system is also used sporadically to treat vestibular disorders in humans (e.g., in vestibular schwannoma, intractable Menière’s disease) [186-188]. However, a recently published prospective controlled trial comparing the intranasal application of betahistine against placebo in patients undergoing vestibular neurectomy failed to show significant group effects [189].

Given these considerations, it appears that there are still some problems with translating positive preclinical experimental data into the clinical setting, which may be explained by the special betahistine mode of action and metabolism. The mechanisms are outlined in the following chapters.

5.5 Betahistine Mechanism of Action

As evoked above, betahistine has the potential to modulate peripheral and central vestibular networks and thus improve pathophysiology of various vestibular disorders based on its specific mode of action.

5.5.1 Antagonistic Action on Histamine H3 Autoreceptors and Heteroreceptors

Betahistine is a partial H1R agonist and H3R antagonist. Different mechanisms account for the effect of betahistine on the restoration of vestibular function. It is now well established that histamine H3 autoreceptor mediates autoinhibition of brain histamine release and autoregulation of histamine synthesis [43, 190-193]. The histamine H3 heteroreceptor mediates autoinhibition of neurotransmitters such as glutamate, GABA, acetylcholine, norepinephrine, dopamine, serotonin, and peptides [40, 194, 195]. These neurotransmitters are all located in the VNs and play a role in regulating vestibular functions and the compensation process [72].

Through blocking the histamine H3 autoreceptors, betahistine increases the synthesis and release of histamine in the TMN and the VN, as shown by immunohistochemistry, in situ hybridization and binding to H3R methods and improves vestibular compensation in the UVN cat model [37, 38, 68, 91, 92, 196]. Thus, betahistine may increase histamine release, which may bind to H1R and H2R in the VN, leading to depolarization which may participate in restoring balanced activity between the deafferented and intact VN.

5.5.2 Agonistic Action on Histamine H1 Receptors

Betahistine can restore electrophysiological balance between the VNCs either by histamine depolarization action on central vestibular neurons expressing H1R or H2R or by agonistic action on H1R located on vestibular excitatory neurons on the deafferented side. This electrophysiological balance is necessary for the vestibular compensation (Fig. 8).

Betahistine has also been demonstrated to restore electrophysiological balance between homologous VN and promotes a faster vestibular compensation by reducing activity in the contralateral VN through its agonistic effect on H1R located on inhibitory GABAergic vestibular commissural neurons in the deafferented MVN [36]. This H1 receptor-mediated asymmetric activation of the vestibular commissural inhibitory system participate in rebalancing the two medial vestibular nuclei and contributes to recovery of both static and dynamic symptoms in locomotion and motor coordination.

In addition to this central mechanism of action, betahistine could reduce both vestibular receptors and afferent vestibular neurons resting firing rate leading to a decrease in the sensory input from the vestibular endorgans [72, 79, 197, 198]. This effect of betahistine on the intact side may restore an electrophysiological homeostasis between the two peripheral vestibular systems. Betahistine could also restore the homeostasis of endolymphatic fluid by acting on H3R and H1R [76, 170]. This could be a way to reduce the increased pressure observed in the endolymphatic hydrops, which is considered as the pathophysiological correlate of Menière's disease [170].

5.5.3 Action of Betahistine on Histaminergic Glial Receptors Leading to Restauration of Excitability

Betahistine could enhance excitability in the deafferented vestibular environment by an action on histamine receptors carried by glial cells and thus restore an electrophysiological balance between the two VNCs. It is well known that astrocytes and microglial cells play a crucial role in regulating brain circuit activity through dynamic interactions with neurons. Astrocytes can modulate neuronal network excitability thanks to different processes, such as K+ clearance [199] or intracellular Ca2+ elevations regulating release of gliotransmitters and neuronal excitability [200]. The expression of H1R, H2R, and H3R has been identified on astrocytes [201]. Histamine interacts with the H1R expressed by astrocytes and leads to the release of glutamate in a concentration-dependent manner in cell cultures [202]. This mechanism increasing glutamate concentration might occur in the deafferented VNs, leading to a higher excitability thus enhancing the restoration of activity between the two VNCs and vestibular compensation. Moreover, H1R regulates the glutamate clearance to avoid the excitotoxic effect [203]. Microglia also controls neuronal network excitability via BDNF signaling [204]. Furthermore, microglia is involved in the oligodendrocyte progenitor cell homeostasis and the myelin components [205], which are capital for the excitability. Since microglial cells express all H1R, H2R, H3R and H4R [114], the increase in histamine promoted by betahistine could intervene on these key mechanisms in order to restore an electrophysiological balance and thus improve vestibular compensation.

5.5.4 Clinical use of Betahistine

Previous clinical studies on the use of betahistine in various vestibular disorders often neglected its specific pharmacokinetic properties when applied via an oral route. Betahistine undergoes extensive first-pass metabolism and therefore has short biological half-life (3-4 hours). The lack of efficacy of betahistine in vestibular disorders could be due to its fast metabolism, given that 95% of the drug is rapidly metabolized by the monoamine oxidase a/b (MAO). Furthermore, genetic polymorphism may cause different rates of metabolism across patients. To increase efficacy in patients with high metabolism, the daily dose may need to be higher and/or the treatment duration longer. Combination of betahistine with a MAO inhibitor (such as selegiline or rasagiline) could also improve its effectiveness in patients with vestibular disorders, as the plasma level of betahistine may rise up by factor 100 (unpublished data). In fact, a low betahistine dose (0.2 mg/kg) co-administrated with selegiline (1 mg/kg) accelerated balance recovery in UVN animals similarly to a single-drug treatment with a 10-times higher betahistine dose (2 mg/kg) [38]. This data strongly supports that the betahistine effect is dependent on its plasma bioavailability. Taken together, co-administration of betahistine with selegiline could be a promising pharmacological therapy both for patients with Menière's disease and AUVP. Changing the route of administration could also be an interesting track given the presence of high concentration of MAO in the digestive tract. One possibility would be to administer betahistine through the nasal route, which would bypass the digestive system and reduce its metabolism. This new administration route has been recently tested in a double-blind clinical study [189].

Finally, pharmacokinetic studies have shown that betahistine is transformed into aminoethylpyridine and hydroxyethylpyridine at the hepatic level and is then excreted as pyridylacetic acid in urine. It was shown that aminoethylpyridine was able to reduce the resting discharge of ampullar receptors like betahistine [206]. In addition, aminoethylpyridine and hydroxyethylpyridine, were found to induce similar effects on the micro-circulation than betahistine in the guinea pig model [165]. This might be of some clinical interest. Based on these data, the anti-vertigo action of betahistine may initially be achieved by the drug itself and then sustained by its metabolites. A therapeutic perspective would be to use betahistine as well as its metabolites.

6 FUTURE DEVELOPMENT OF HISTAMINE-RECEPTOR MODULATORS

6.1 Histamine H4 Receptor Modulators

Following the demonstration of a preferred expression of H4R in rodent vestibular primary neurons [71], selective H4R antagonists have been found to have a strong inhibitory effect on the excitability of both isolated mammalian vestibular primary neurons [71] and rodent vestibule explants [74]. Since H3R antagonist used in pharmacology, such has betahistine, share this peripheral effect [78], these results suggested a potential application of H4R antagonists in vestibular disorders.

Recently, a selective inhibitor of the H4R, SENS-111, was given orally to healthy volunteers who underwent caloric tests. This administration significantly improved the latency of vertigo appearance, disappearance and duration, as well as the European Evaluation of Vertigo questionnaire parameters compared to baseline [143]. Although the drug had no significant effect on nystagmus, this study suggests that SENS-111 may be a promising drug for managing dizziness associated with vestibular disorder. Another recent investigation in Menière’s disease patients reported that a particular H4R gene variant, rs77485247 polymorphism, may be linked to an increased risk of Menière’s disease [207]. H4R are highly expressed on peripheral blood mononuclear cells [208], which are critical components of the immune system. There is growing evidence of an autoimmune background for Menière’s disease in a subset of patients [209] and that proinflammatory cytokines contribute to pathogenesis of Menière’s disease [137]. These findings suggest a connection between inflammation, histamine receptors, and vestibular disorders.

6.2 Histamine, Neuroinflammation and H4 Receptor

As mentioned above, microglial cells, which are the innate immune cells in the central nervous system and primarily express H4R [67], can be activated by histamine, resulting in the production of pro-inflammatory cytokines [114]. This observation is supported by data showing that intracerebroventricular infusion of H4R agonists increased the total microglia cell number in a dose-dependent manner [116]. In a rat model of Parkinson’s pathology, Zhou and al, showed that H4R antagonist inhibits pro-inflammatory microglia response and prevents the progression of Parkinson-like pathology and behavior [210]. Given the presence of H4R in microglial cells and the high level of expression of these cells in the VN following vestibular loss, it can be postulated that histamine may play a role in the inflammatory response observed in this model of vestibulopathy. Therefore, the use of H4R antagonist pharmacological compounds may be appropriate to inhibit the inflammation associated with certain vestibular pathologies, such as AUVP.

CONCLUSION

As evidenced by the wide expression of its various specific receptors throughout the vestibular sensory network, histamine appears to be a major modulator of vestibular signal processing. However, its precise actions on the detection, transmission and integration of vestibular sensory information in normal physiological conditions, which could globally favor the activation of the vestibule in case of need, still remain to be specified. The fine interactions between the histaminergic system and the inflammation modulating cells reveal a neuroprotective action of histamine, which could be valuable in an inflammatory context associated with peripheral vestibular damage. In addition, the extensive histamine receptor expression across the peripheral and central vestibular network offers a large opportunity for pharmacological modulation of the central compensation process with the hope of optimizing functional restoration of peripheral vestibular loss. Current efforts to improve the delivery of pharmacological compounds that have already proven their efficacy on the symptoms of vestibular disorders should soon lead to more targeted and effective drugs for vestibular pathologies.

ACKNOWLEDGEMENTS

Declared none.

LIST OF ABBREVIATIONS

H1R Histamine Type 1 Receptor

HR Histamine Receptors

IVN Inferior Vestibular Nuclei

LVN Lateral Vestibular Nuclei

MVN Median Vestibular Nuclei

NF-kB Nuclear Factor-kappa B

SVN Superior Vestibular Nuclei

TNF-α Tumor Necrosis Factor-alpha

UVN Unilateral Vestibular Neurectomy

VN Vestibular Nuclei

VNC Vestibular Nuclei Complex

VOR Vestibulo-ocular Reflex

VSR Vestibulo-spinal Reflex

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

This review work was supported by the Ministère de l’Enseignement Supérieur et de la Recherche and CNRS (UMR 7291 AMU).

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

Fig. (1) Anatomic and functional organization of the vestibular system. The vestibular nerve is in contact with the sensory hair cells located in the peripheral vestibular system. This nerve projects ipsilaterally to the four vestibular nuclei (VNs): superior, lateral, medial and inferior, located in the brainstem. From these nuclei, several output pathways exist. The vestibulo-oculomotor pathway originates from the lateral nuclei that project to the oculomotor nuclei via the medial longitudinal fasciculus (MLF), allowing the stabilization of gaze during head movements. The vestibulospinal pathway includes a lateral vestibulospinal fasciculus (LVSF) that connects the ipsilateral lateral VN to the spinal cord and a medial vestibulospinal fasciculus (MVSF) that connects the contralateral medial, inferior, and lateral VNs to the musculature of the neck and upper body axis. This organization establishes postural control and muscle tone. The vestibulo-vegetative pathway consists of the superior and medial VNs that activate the vagus nerve, responsible for vital functions. VNs are linked to several neurovegetative nuclei, such as the dorsal nucleus of the vagus nerve (DNV), solitary nucleus (NTS) and area postrema. Various vestibulo-cortical pathways originate from all VNs and project bilaterally to the cortex. The diversity of output from the VNs underlines the broad role of the vestibular system in posturo-locomotor, oculomotor and higher cognitive functions. The balanced resting activity between the bilateral VNs is crucial for these functions. Created with bioRender.

Fig. (2) Unbalanced resting activity within the vestibular nuclei complex and vestibular syndrome expression after unilateral vestibular neurectomy. Electrophysiological imbalance after unilateral vestibular neurectomy (UVN) between the bilateral vestibular nuclei (VNs) is responsible for the acute vestibular syndrome. After UVN, the ipsilateral VNs are deafferented and show reduced excitability in contrast to the VNs contralateral to the lesion. This effect is explained by the absence of vestibular peripheral inputs from the lesion side. The syndrome generated by this unbalanced resting activity in the VNs is composed of oculomotor, posturo-locomotor, vegetative and perceptive-cognitive signs and symptoms. Over time, the syndrome disappears as neuroplasticity mechanisms result in a rebalanced activity between the bilateral VNs - a mechanism called vestibular compensation. Created with bioRender.

Fig. (3) Synthesis, catabolism, and distribution of histamine in the adult mammalian brain. (a) Neuronal histamine is synthetized from the amino acid L-histidine by the L-histidine decarboxylase enzyme. Histamine is then degraded by two enzymes, histamine N-methyltransferase and monoamine oxidase, resulting in tele-methylimidazoleacetic. (b) Histaminergic neurons are restricted to the tuberomammillary nucleus of the posterior hypothalamus, from where they project widely into the brain, including in the vestibular nuclei complexes. Created with bioRender.

Fig. (4) Localization of histaminergic receptors in the central (a) and peripheral (b) vestibular system. (a) The vestibular nuclei complexes (VNCs) contain three types of histaminergic receptors (HR). The secondary vestibular neurons express histaminergic type 1 (H1R) and histaminergic type 2 (H2R) receptor while the afferents from the tuberomammillary histaminergic neurons (in purple) express the histaminergic type 3 (H3R) autoreceptor. It should be noted that other afferents releasing various neurotransmitter in the VNCs can express a histaminergic type 3 (H3R) heteroreceptor. (b) The peripheral vestibular system contains all types of histaminergic receptors. Every type of HR is expressed in the Scarpa’s ganglion while only H1R and H3R are expressed in the endolymphatic sac. H1R, H3R and H4R are expressed in both type II and type I vestibular hair cells, while H2R is only found in type I vestibular hair cells. These schematic representations were created based on information found in [36, 58, 69] for the upper part and [71-73] for the lower part. Created with biorender.

Fig. (5) Involvement of histamine in vestibular compensation after unilateral vestibular neurectomy. The unilateral vestibular neurectomy (UVN) leads to an electrophysiological imbalance between the vestibular nuclei, which is conveyed to the posterior hypothalamus through direct vestibulo-hypothalamic loops. In consequence, the synthesis and release of histamine (HA) from the tuberomammillary nucleus (TMN) to the deafferented vestibular nuclei (VN) increases. In VN, HA will bind to the three types of histamine receptors. By the histamine H3 receptor (H3R), more HA will be synthesized and released because of the abolition of the negative feedback. By the histamine H1 (H1R) and H2 (H2R) receptors, HA will restore the electrophysiological imbalance underlying the vestibular compensation. Created with bioRender.

Fig. (6) Dual role of histamine depending on the context of the cellular environment. Histamine has a rather pro-inflammatory or anti-inflammatory role via the four histamine receptors expressed by microglia, depending on the micro-environment. Histamine has a pro-inflammatory role via the histamine H1 (H1R) and H4 (H4R) in a physiological context. Their activation leads to increased secretion of pro-inflammatory factors such as tumor necrosis factor-alpha (TNF-α), interleukin 6 (IL-6), interleukin 1 beta (IL-1β) and prostaglandin E2 (PGE2), but also to increased phagocytosis and reactive oxygen species (ROS) production. Conversely, histamine has a rather anti-inflammatory role in an inflammatory context via the histamine H2 (H2R) and H3 (H3R) receptors. Their activation leads to the inhibition of the inflammatory process of lipopolysaccharide (LPS), to the increase of secretion of anti-inflammatory factors such as interleukin 10 (IL-10) and interleukin 4 (IL-4), to the inhibition of pro-inflammatory factors (TNF-α and IL-1β), cluster of differentiation 14 (CD14) and interferon-gamma (IFN-γ). Finally, activation of these receptors also decreases phagocytosis and ROS production. Created with bioRender.

Fig. (7) Anti-inflammatory and neuroprotective effect of betahistine after vestibular lesion. The vestibular lesion induces an inflammatory context in the deafferented vestibular nuclei (VN). Betahistine inhibits the histamine H3 receptor (H3R), which leads to the activation of a cAMP/PKA/CREB signaling pathway that induces glial-mediated inhibition of inflammation. These elements lead to a neuroprotective environment and would explain the decrease of neuronal differentiation in deafferented VN under this treatment. Created with bioRender.

Fig. (8) Pharmacological mechanisms of betahistine underlying the rebalanced activity between the deafferented and intact vestibular nuclei after a vestibular lesion. Betahistine increases histamine (HA) synthesis and secretion by blocking histamine H3 (H3R) auto-receptors. Several events participate in the restoration of vestibular functions. Histaminergic activation of histamine H1 receptor (H1R) by betahistine and histamine and of histamine H2 receptor (H2R) by histamine in excitatory neurons of the deafferented vestibular nuclei (VN) induces depolarization. Betahistine and histamine bind to H1R on ipsilesional commissural GABAergic neurons, inhibiting the VN contralateral to the lesion. Peripherally, betahistine could increase the cochlear and vestibular blood flow, improving the microcirculation of the inner ear via histamine H3 heteroreceptors, while activation of H1R by betahistine and histamine induces a reduction in the activity of intact vestibular inputs. Created with bioRender.
==== Refs
REFERENCES

1 Kingma H. van de Berg R. Anatomy, physiology, and physics of the peripheral vestibular system. Handb. Clin. Neurol. 2016 137 1 16 10.1016/B978-0-444-63437-5.00001-7 27638059
2 Angelaki D.E. Cullen K.E. Vestibular system: The many facets of a multimodal sense. Annu. Rev. Neurosci. 2008 31 1 125 150 10.1146/annurev.neuro.31.060407.125555 18338968
3 Azzena G.B. Mameli O. Tolu E. Distribution of visual input to the vestibular nuclei. Arch. Ital. Biol. 1980 118 2 196 204 7469664
4 Cullen K.E. The vestibular system: Multimodal integration and encoding of self-motion for motor control. Trends Neurosci. 2012 35 3 185 196 10.1016/j.tins.2011.12.001 22245372
5 Gdowski G.T. McCrea R.A. Neck proprioceptive inputs to primate vestibular nucleus neurons. Exp. Brain Res. 2000 135 4 511 526 10.1007/s002210000542 11156315
6 MacKinnon C.D. Sensorimotor anatomy of gait, balance, and falls. Handb. Clin. Neurol. 2018 159 3 26 10.1016/B978-0-444-63916-5.00001-X 30482322
7 McCall A.A. Miller D.M. DeMayo W.M. Bourdages G.H. Yates B.J. Vestibular nucleus neurons respond to hindlimb movement in the conscious cat. J. Neurophysiol. 2016 116 4 1785 1794 10.1152/jn.00414.2016 27440244
8 Brandt T. Dieterich M. Thalamocortical network: A core structure for integrative multimodal vestibular functions. Curr. Opin. Neurol. 2019 32 1 154 164 10.1097/WCO.0000000000000638 30461462
9 Waele C. Baudonniere P.M. Lepecq J.C. Huy P.T.B. Vodal P.P. Vestibular projections in the human cortex. Exp. Brain Res. 2001 141 4 541 551 10.1007/s00221-001-0894-7 11810147
10 Dieterich M. Brandt T. The parietal lobe and the vestibular system. Handb. Clin. Neurol. 2018 151 119 140 10.1016/B978-0-444-63622-5.00006-1 29519455
11 Lopez C. Blanke O. The thalamocortical vestibular system in animals and humans. Brain Res. Brain Res. Rev. 2011 67 1-2 119 146 10.1016/j.brainresrev.2010.12.002 21223979
12 Lopez C. Making sense of the body: The role of vestibular signals. Multisens. Res. 2015 28 5-6 525 557 10.1163/22134808-00002490 26595955
13 Lopez C. The vestibular system. Curr. Opin. Neurol. 2016 29 1 74 83 10.1097/WCO.0000000000000286 26679566
14 Brandt T. Schautzer F. Hamilton D.A. Brüning R. Markowitsch H.J. Kalla R. Darlington C. Smith P. Strupp M. Vestibular loss causes hippocampal atrophy and impaired spatial memory in humans. Brain 2005 128 11 2732 2741 10.1093/brain/awh617 16141283
15 Brandt T. Dieterich M. ‘Excess anxiety’ and ‘less anxiety’: Both depend on vestibular function. Curr. Opin. Neurol. 2020 33 1 136 141 10.1097/WCO.0000000000000771 31743237
16 Cullen K.E. Vestibular processing during natural self-motion: implications for perception and action. Nat. Rev. Neurosci. 2019 20 6 346 363 10.1038/s41583-019-0153-1 30914780
17 Jacob P.Y. Poucet B. Liberge M. Save E. Sargolini F. Vestibular control of entorhinal cortex activity in spatial navigation. Front. Integr. Nuerosci. 2014 8 38 10.3389/fnint.2014.00038 24926239
18 McKeown J. McGeoch P.D. Grieve D.J. The influence of vestibular stimulation on metabolism and body composition. Diabet. Med. 2020 37 1 20 28 10.1111/dme.14166 31667892
19 Smith P.F. Recent developments in the understanding of the interactions between the vestibular system, memory, the hippocampus, and the striatum. Front. Neurol. 2022 13 986302 10.3389/fneur.2022.986302 36119673
20 Tighilet B. Chabbert C. Adult neurogenesis promotes balance recovery after vestibular loss. Prog. Neurobiol. 2019 174 28 35 10.1016/j.pneurobio.2019.01.001 30658127
21 Curthoys I.S. Vestibular compensation and substitution. Curr. Opin. Neurol. 2000 13 1 27 30 10.1097/00019052-200002000-00006 10719646
22 Curthoys I.S. Halmagyi G.M. Vestibular compensation: A review of the oculomotor, neural, and clinical consequences of unilateral vestibular loss. J. Vestib. Res. 1995 5 2 67 107 10.3233/VES-1995-5201 7743004
23 Lacour M. Helmchen C. Vidal P.P. Vestibular compensation: The neuro-otologist’s best friend. J. Neurol. 2016 263 S1 54 64 10.1007/s00415-015-7903-4 27083885
24 Smith P.F. Curthoys I.S. Neuronal activity in the ipsilateral medial vestibular nucleus of the guinea pig following unilateral labyrinthectomy. Brain Res. 1988 444 2 308 319 10.1016/0006-8993(88)90939-0 3359298
25 Smith P.F. Curthoys I.S. Neuronal activity in the contralateral medial vestibular nucleus of the guinea pig following unilateral labyrinthectomy. Brain Res. 1988 444 2 295 307 10.1016/0006-8993(88)90938-9 3359297
26 Zennou-Azogui Y. Borel L. Lacour M. Ez-Zaher L. Ouaknine M. Recovery of head postural control following unilateral vestibular neurectomy in the cat. Neck muscle activity and neuronal correlates in Deiters’ nuclei. Acta Otolaryngol. 1993 113 sup509 5 19 10.3109/00016489309130556 8285044
27 Antons M. Lindner M. Eilles E. Günther L. Delker A. Branner C. Krämer A. Beck R. Oos R. Wuehr M. Ziegler S. Strupp M. Zwergal A. Dose- and application route-dependent effects of betahistine on behavioral recovery and neuroplasticity after acute unilateral labyrinthectomy in rats. Front. Neurol. 2023 14 1175481 10.3389/fneur.2023.1175481 37538257
28 Darlington C.L. Smith P.F. Molecular mechanisms of recovery from vestibular damage in mammals: Recent advances. Prog. Neurobiol. 2000 62 3 313 325 10.1016/S0301-0082(00)00002-2 10840152
29 Dieringer N. ‘Vestibular compensation’: neural plasticity and its relations to functional recovery after labyrinthine lesions in frogs and other vertebrates. Prog. Neurobiol. 1995 46 2-3 97 129 7568917
30 Dutia M.B. Mechanisms of vestibular compensation: Recent advances. Curr. Opin. Otolaryngol. Head Neck Surg. 2010 18 5 420 424 10.1097/MOO.0b013e32833de71f 20693901
31 Grosch M. Lindner M. Bartenstein P. Brandt T. Dieterich M. Ziegler S. Zwergal A. Dynamic whole-brain metabolic connectivity during vestibular compensation in the rat. Neuroimage 2021 226 117588 10.1016/j.neuroimage.2020.117588 33249212
32 Lacour M. Restoration of vestibular function: Basic aspects and practical advances for rehabilitation. Curr. Med. Res. Opin. 2006 22 9 1651 1659 10.1185/030079906X115694 16968568
33 Lacour M. Tighilet B. Plastic events in the vestibular nuclei during vestibular compensation: The brain orchestration of a “deafferentation” code. Restor. Neurol. Neurosci. 2010 28 1 19 35 10.3233/RNN-2010-0509 20086280
34 Paterson J.M. Short D. Flatman P.W. Seckl J.R. Aitken A. Dutia M.B. Changes in protein expression in the rat medial vestibular nuclei during vestibular compensation. J. Physiol. 2006 575 3 777 788 10.1113/jphysiol.2006.112409 16825307
35 Smith P.F. Curthoys I.S. Mechanisms of recovery following unilateral labyrinthectomy: A review. Brain Res. Brain Res. Rev. 1989 14 2 155 180 10.1016/0165-0173(89)90013-1 2665890
36 Chen Z.P. Zhang X.Y. Peng S.Y. Yang Z.Q. Wang Y.B. Zhang Y.X. Chen X. Wang J.J. Zhu J.N. Histamine H1 receptor contributes to vestibular compensation. J. Neurosci. 2019 39 3 420 433 10.1523/JNEUROSCI.1350-18.2018 30413645
37 Tighilet B. Mourre C. Trottier S. Lacour M. Histaminergic ligands improve vestibular compensation in the cat: Behavioural, neurochemical and molecular evidence. Eur. J. Pharmacol. 2007 568 1-3 149 163 10.1016/j.ejphar.2007.04.052 17573072
38 Tighilet B. Léonard J. Watabe I. Bernard-Demanze L. Lacour M. Betahistine treatment in a cat model of vestibular pathology: Pharmacokinetic and pharmacodynamic approaches. Front. Neurol. 2018 9 431 10.3389/fneur.2018.00431 29942281
39 Redon C. Lopez C. Bernard-Demanze L. Dumitrescu M. Magnan J. Lacour M. Borel L. Betahistine treatment improves the recovery of static symptoms in patients with unilateral vestibular loss. J. Clin. Pharmacol. 2011 51 4 538 548 10.1177/0091270010369241 20940335
40 Brown R.E. Stevens D.R. Haas H.L. The physiology of brain histamine. Prog. Neurobiol. 2001 63 6 637 672 10.1016/S0301-0082(00)00039-3 11164999
41 Katoh Y. Niimi M. Yamamoto Y. Kawamura T. Morimoto-Ishizuka T. Sawada M. Takemori H. Yamatodani A. Histamine production by cultured microglial cells of the mouse. Neurosci. Lett. 2001 305 3 181 184 10.1016/S0304-3940(01)01835-3 11403935
42 Schwartz J.C. Arrang J.M. Garbarg M. Pollard H. Ruat M. Histaminergic transmission in the mammalian brain. Physiol. Rev. 1991 71 1 1 51 10.1152/physrev.1991.71.1.1 1846044
43 Haas H. Panula P. The role of histamine and the tuberomamillary nucleus in the nervous system. Nat. Rev. Neurosci. 2003 4 2 121 130 10.1038/nrn1034 12563283
44 Panula P. Yang H.Y. Costa E. Histamine-containing neurons in the rat hypothalamus. Proc. Natl. Acad. Sci. USA 1984 81 8 2572 2576 10.1073/pnas.81.8.2572 6371818
45 Panula P. Pirvola U. Auvinen S. Airaksinen M.S. Histamine-immunoreactive nerve fibers in the rat brain. Neuroscience 1989 28 3 585 610 10.1016/0306-4522(89)90007-9 2710333
46 Tighilet B. Lacour M. Distribution of histaminergic axonal fibres in the vestibular nuclei of the cat. Neuroreport 1996 7 4 873 878 10.1097/00001756-199603220-00008 8724664
47 Hu W. Chen Z. The roles of histamine and its receptor ligands in central nervous system disorders: An update. Pharmacol. Ther. 2017 175 116 132 10.1016/j.pharmthera.2017.02.039 28223162
48 Chang R.S.L. Tran V.T. Snyder S.H. Heterogeneity of histamine H1-receptors: species variations in [3H]mepyramine binding of brain membranes. J. Neurochem. 1979 32 6 1653 1663 10.1111/j.1471-4159.1979.tb02276.x 448359
49 Bárbara A. Aceves J. Arias-Montaño J.A. Histamine H1 receptors in rat dorsal raphe nucleus: Pharmacological characterisation and linking to increased neuronal activity. Brain Res. 2002 954 2 247 255 10.1016/S0006-8993(02)03352-8 12414108
50 Korotkova T.M. Sergeeva O.A. Ponomarenko A.A. Haas H.L. Histamine excites noradrenergic neurons in locus coeruleus in rats. Neuropharmacology 2005 49 1 129 134 10.1016/j.neuropharm.2005.03.001 15992588
51 Bouthenet M.L. Ruat M. Sales N. Garbarg M. Schwartz J.C. A detailed mapping of hist amine H1-receptors in guinea-pig central nervous system established by autoradiography with [125I]iodobolpyramine. Neuroscience 1988 26 2 553 600 10.1016/0306-4522(88)90167-4 3173689
52 Jin C.Y. Panula P. The laminar histamine receptor system in human prefrontal cortex suggests multiple levels of histaminergic regulation. Neuroscience 2005 132 1 137 149 10.1016/j.neuroscience.2004.12.017 15780473
53 Yanai K. Tashiro M. The physiological and pathophysiological roles of neuronal histamine: An insight from human positron emission tomography studies. Pharmacol. Ther. 2007 113 1 1 15 10.1016/j.pharmthera.2006.06.008 16890992
54 Kanba S. Richelson E. Histamine H1 receptors in human brain labelled with [3H]Doxepin. Brain Res. 1984 304 1 1 7 10.1016/0006-8993(84)90856-4 6146381
55 Martinez-Mir M.I. Pollard H. Moreau J. Arrang J.M. Ruat M. Traiffort E. Schwartz J.C. Palacios J.M. Three histamine receptors (H1, H2 and H3) visualized in the brain of human and non-human primates. Brain Res. 1990 526 2 322 327 10.1016/0006-8993(90)91240-H 1979518
56 Schneider E.H. Neumann D. Seifert R. Modulation of behavior by the histaminergic system: Lessons from H1R-and H2R-deficient mice. Neurosci. Biobehav. Rev. 2014 42 252 266 10.1016/j.neubiorev.2014.03.009 24661982
57 Karlstedt K. Senkas A. Åhman M. Panula P. Regional expression of the histamine H2 receptor in adult and developing rat brain. Neuroscience 2001 102 1 201 208 10.1016/S0306-4522(00)00464-4 11226684
58 Vizuete M.L. Traiffort E. Bouthenet M.L. Ruat M. Souil E. Tardivel-Lacombe J. Schwartz J.C. Detailed mapping of the histamine H2 receptor and its gene transcripts in guinea-pig brain. Neuroscience 1997 80 2 321 343 10.1016/S0306-4522(97)00010-9 9284338
59 Traiffort E. Pollard H. Moreau J. Ruat M. Schwartz J.C. Martinez-Mir M.I. Palacios J.M. Pharmacological characterization and autoradiographic localization of histamine H2 receptors in human brain identified with [125I]iodoaminopotentidine. J. Neurochem. 1992 59 1 290 299 10.1111/j.1471-4159.1992.tb08903.x 1351926
60 Yoshikawa T. Nakamura T. Yanai K. Histaminergic neurons in the tuberomammillary nucleus as a control center for wakefulness. Br. J. Pharmacol. 2021 178 4 750 769 10.1111/bph.15220 32744724
61 Chazot P.L. Hann V. Wilson C. Lees G. Thompson C.L. Immunological identification of the mammalian H3 histamine receptor in the mouse brain. Neuroreport 2001 12 2 259 262 10.1097/00001756-200102120-00016 11209931
62 Pollard H. Moreau J. Arrang J.M. Schwartz J.C. A detailed autoradiographic mapping of histamine H3 receptors in rat brain areas. Neuroscience 1993 52 1 169 189 10.1016/0306-4522(93)90191-H 8381924
63 Pillot C. Heron A. Cochois V. Tardivel-Lacombe J. Ligneau X. Schwartz J.C. Arrang J.M. A detailed mapping of the histamine H3 receptor and its gene transcripts in rat brain. Neuroscience 2002 114 1 173 193 10.1016/S0306-4522(02)00135-5 12207964
64 Anichtchik O.V. Peitsaro N. Rinne J.O. Kalimo H. Panula P. Distribution and modulation of histamine H(3) receptors in basal ganglia and frontal cortex of healthy controls and patients with Parkinson’s disease. Neurobiol. Dis. 2001 8 4 707 716 10.1006/nbdi.2001.0413 11493035
65 Strakhova M.I. Nikkel A.L. Manelli A.M. Hsieh G.C. Esbenshade T.A. Brioni J.D. Bitner R.S. Localization of histamine H4 receptors in the central nervous system of human and rat. Brain Res. 2009 1250 41 48 10.1016/j.brainres.2008.11.018 19046950
66 Shan L. Bossers K. Luchetti S. Balesar R. Lethbridge N. Chazot P.L. Bao A.M. Swaab D.F. Alterations in the histaminergic system in the substantia nigra and striatum of Parkinson’s patients: a postmortem study. Neurobiol. Aging 2012 33 7 1488.e1 1488.e13 10.1016/j.neurobiolaging.2011.10.016 22118942
67 Schneider E.H. Seifert R. The histamine H4-receptor and the central and peripheral nervous system: A critical analysis of the literature. Neuropharmacology 2016 106 116 128 10.1016/j.neuropharm.2015.05.004 25986697
68 Tighilet B. Trottier S. Mourre C. Chotard C. Lacour M. Betahistine dihydrochloride interaction with the histaminergic system in the cat: Neurochemical and molecular mechanisms. Eur. J. Pharmacol. 2002 446 1-3 63 73 10.1016/S0014-2999(02)01795-8 12098586
69 Tighilet B. Trottier S. Mourre C. Lacour M. Changes in the histaminergic system during vestibular compensation in the cat. J. Physiol. 2006 573 3 723 739 10.1113/jphysiol.2006.107805 16613878
70 Ruat M. Traiffort E. Arrang J.M. Leurs R. Schwartz J.C. Cloning and tissue expression of a rat histamine H2-receptor gene. Biochem. Biophys. Res. Commun. 1991 179 3 1470 1478 10.1016/0006-291X(91)91738-X 1930188
71 Desmadryl G. Gaboyard-Niay S. Brugeaud A. Travo C. Broussy A. Saleur A. Dyhrfjeld-Johnsen J. Wersinger E. Chabbert C. Histamine H 4 receptor antagonists as potent modulators of mammalian vestibular primary neuron excitability. Br. J. Pharmacol. 2012 167 4 905 916 10.1111/j.1476-5381.2012.02049.x 22624822
72 Soto E. Vega R. Neuropharmacology of vestibular system disorders. Curr. Neuropharmacol. 2010 8 1 26 40 10.2174/157015910790909511 20808544
73 Takumida M. Takumida H. Anniko M. Localization of histamine (H1, H2, H3 and H4) receptors in mouse inner ear. Acta Otolaryngol. 2016 136 6 537 544 10.3109/00016489.2015.1136433 26854127
74 Wersinger E. Gaboyard-Niay S. Travo C. Soto E. Baez A. Vega R. Brugeaud A. Chabbert C. Symptomatic treatment of vestibular deficits: Therapeutic potential of histamine H4 receptors. J. Vestib. Res. 2013 23 3 153 159 10.3233/VES-130493 24177347
75 Eatock R.A. Songer J.E. Vestibular hair cells and afferents: Two channels for head motion signals. Annu. Rev. Neurosci. 2011 34 1 501 534 10.1146/annurev-neuro-061010-113710 21469959
76 Møller M.N. Kirkeby S. Vikeså J. Nielsen F.C. Caye-Thomasen P. Expression of histamine receptors in the human endolymphatic sac: The molecular rationale for betahistine use in Menieres disease. Eur. Arch. Otorhinolaryngol. 2016 273 7 1705 1710 10.1007/s00405-015-3731-5 26208913
77 Housley G.D. Norris C.H. Guth P.S. Histamine and related substances influence neurotransmission in the semicircular canal. Hear. Res. 1988 35 1 87 97 10.1016/0378-5955(88)90043-3 3263349
78 Chávez H. Vega R. Soto E. Histamine (H3) receptors modulate the excitatory amino acid receptor response of the vestibular afferents. Brain Res. 2005 1064 1-2 1 9 10.1016/j.brainres.2005.10.027 16310756
79 Botta L. Mira E. Valli S. Perin P. Zucca G. Valli P. Effects of betahistine on vestibular receptors of the frog. Acta Otolaryngol. 1998 118 4 519 523 10.1080/00016489850154658 9726676
80 Li B. Zhang X-Y. Yang A-H. Peng X.C. Chen Z.P. Zhou J.Y. Chan Y.S. Wang J.J. Zhu J.N. Histamine increases neuronal excitability and sensitivity of the lateral vestibular nucleus and promotes motor behaviors via hcn channel coupled to H2 receptor. Front. Cell. Neurosci. 2017 10 300 10.3389/fnagi.2017.00300 28119568
81 Peng S.Y. Zhuang Q.X. He Y.C. Zhu J.N. Wang J.J. Histamine excites neurons of the inferior vestibular nucleus in rats by activation of H1 and H2 receptors. Neurosci. Lett. 2013 541 87 92 10.1016/j.neulet.2013.02.040 23466693
82 Phelan K.D. Nakamura J. Gallagher J.P. Histamine depolarizes rat medial vestibular nucleus neurons recorded intracellularly in vitro. Neurosci. Lett. 1990 109 3 287 292 10.1016/0304-3940(90)90009-X 2139500
83 Serafin M. Khateb A. Vibert N. Vidal P.P. Mühlethaler M. Medial vestibular nucleus in the guinea-pig: Histaminergic receptors. I. An in vitro study. Exp. Brain Res. 1993 93 2 242 248 10.1007/BF00228391 8387929
84 Wang J.J. Dutia M.B. Effects of histamine and betahistine on rat medial vestibular nucleus neurones: Possible mechanism of action of anti-histaminergic drugs in vertigo and motion sickness. Exp. Brain Res. 1995 105 1 18 24 10.1007/BF00242178 7589314
85 Zhang J. Han X.H. Li H.Z. Zhu J.N. Wang J.J. Histamine excites rat lateral vestibular nuclear neurons through activation of post-synaptic H2 receptors. Neurosci. Lett. 2008 448 1 15 19 10.1016/j.neulet.2008.10.027 18938221
86 Zhuang Q.X. Wu Y.H. Wu G.Y. Zhu J.N. Wang J.J. Histamine excites rat superior vestibular nuclear neurons via postsynaptic H1 and H2 receptors in vitro. Neurosignals 2013 21 3-4 174 183 10.1159/000341980 23006827
87 Takeda N. Morita M. Kubo T. Yamatodani A. Watanabe T. Wada H. Matsunaga T. Histaminergic mechanism of motion sickness. Neurochemical and neuropharmacological studies in rats. Acta Otolaryngol. 1986 101 5-6 416 421 10.3109/00016488609108626 3727976
88 Horii A. Takeda N. Matsunaga T. Yamatodani A. Mochizuki T. Okakura-Mochizuki K. Wada H. Effect of unilateral vestibular stimulation on histamine release from the hypothalamus of rats in vivo. J. Neurophysiol. 1993 70 5 1822 1826 10.1152/jn.1993.70.5.1822 8294957
89 Uno A. Takeda N. Horii A. Morita M. Yamamoto Y. Yamatodani A. Kubo T. Histamine release from the hypothalamus induced by gravity change in rats and space motion sickness. Physiol. Behav. 1997 61 6 883 887 10.1016/S0031-9384(96)00613-0 9177562
90 Yabe T. de Waele C. Serafin M. Vibert N. Arrang J.M. Mühlethaler M. Vidal P.P. Medial vestibular nucleus in the guinea-pig: Histaminergic receptors. Exp. Brain Res. 1993 93 2 249 258 10.1007/BF00228392 8491265
91 Tighilet B. Mourre C. Lacour M. Plasticity of the histamine H3 receptors after acute vestibular lesion in the adult cat. Front. Integr. Nuerosci. 2014 7 87 10.3389/fnint.2013.00087 24427120
92 Tighilet B. Lacour M. Histamine immunoreactivity changes in vestibular-lesioned and histaminergic-treated cats. Eur. J. Pharmacol. 1997 330 1 65 77 10.1016/S0014-2999(97)10124-8 9228415
93 Matsuyama T. Kayahara T. Nomura J. Nakano K. Direct projections from the medial vestibular nucleus to the posterior hypothalamic area in the monkey (Macaca fuscata). Neurosci. Lett. 1996 219 3 199 202 10.1016/S0304-3940(96)13206-7 8971814
94 Kassner S.S. Schöttler S. Bonaterra G.A. Stern-Straeter J. Hormann K. Kinscherf R. Gössler U.R. Proinflammatory activation of peripheral blood mononuclear cells in patients with vestibular neuritis. Audiol. Neurotol. 2011 16 4 242 247 10.1159/000320839 20980744
95 Strupp M. Bisdorff A. Furman J. Hornibrook J. Jahn K. Maire R. Newman-Toker D. Magnusson M. Acute unilateral vestibulopathy/vestibular neuritis: Diagnostic criteria. J. Vestib. Res. 2022 32 5 389 406 10.3233/VES-220201 35723133
96 Le T.N. Westerberg B.D. Lea J. Vestibular neuritis: Recent advances in etiology, diagnostic evaluation, and treatment. Adv. Otorhinolaryngol. 2019 82 87 92 10.1159/000490275 30947184
97 Goudakos J.K. Markou K.D. Franco-Vidal V. Vital V. Tsaligopoulos M. Darrouzet V. Corticosteroids in the treatment of vestibular neuritis: A systematic review and meta-analysis. Otol. Neurotol. 2010 31 2 183 189 10.1097/MAO.0b013e3181ca843d 20009780
98 Strupp M. Zingler V.C. Arbusow V. Niklas D. Maag K.P. Dieterich M. Bense S. Theil D. Jahn K. Brandt T. Methylprednisolone, valacyclovir, or the combination for vestibular neuritis. N. Engl. J. Med. 2004 351 4 354 361 10.1056/NEJMoa033280 15269315
99 Fishman J.M. Burgess C. Waddell A. Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis). Cochrane Libr. 2011 5 CD008607 10.1002/14651858.CD008607.pub2 21563170
100 Kim G. Seo J.H. Lee S.J. Lee D.H. Therapeutic effect of steroids on vestibular neuritis: Systematic review and meta‐analysis. Clin. Otolaryngol. 2022 47 1 34 43 10.1111/coa.13880 34687143
101 Leong K.J. Lau T. Stewart V. Canetti E.F.D. Systematic review and meta‐analysis: Effectiveness of corticosteroids in treating adults with acute vestibular neuritis. Otolaryngol. Head Neck Surg. 2021 165 2 255 266 10.1177/0194599820982910 33525978
102 Dutheil S. Brezun J.M. Leonard J. Lacour M. Tighilet B. Neurogenesis and astrogenesis contribution to recovery of vestibular functions in the adult cat following unilateral vestibular neurectomy: cellular and behavioral evidence. Neuroscience 2009 164 4 1444 1456 10.1016/j.neuroscience.2009.09.048 19782724
103 Dutheil S. Lacour M. Tighilet B. Neurogenic potential of the vestibular nuclei and behavioural recovery time course in the adult cat are governed by the nature of the vestibular damage. PLoS One 2011 6 8 e22262 10.1371/journal.pone.0022262 21853029
104 Dutheil S. Watabe I. Sadlaoud K. Tonetto A. Tighilet B. BDNF signaling promotes vestibular compensation by increasing neurogenesis and remodeling the expression of potassium-chloride cotransporter KCC2 and GABAA receptor in the vestibular Nuclei. J. Neurosci. 2016 36 23 6199 6212 10.1523/JNEUROSCI.0945-16.2016 27277799
105 Rastoldo G. El Mahmoudi N. Marouane E. Pericat D. Watabe I. Toneto A. López-Juárez A. Chabbert C. Tighilet B. Adult and endemic neurogenesis in the vestibular nuclei after unilateral vestibular neurectomy. Prog. Neurobiol. 2021 196 101899 10.1016/j.pneurobio.2020.101899 32858093
106 Campos T.A. Vidal P.P. de Waele C. Evidence for a microglial reaction within the vestibular and cochlear nuclei following inner ear lesion in the rat. Neuroscience 1999 92 4 1475 1490 10.1016/S0306-4522(99)00078-0 10426501
107 Campos-Torres A. Touret M. Vidal P.P. Barnum S. de Waele C. The differential response of astrocytes within the vestibular and cochlear nuclei following unilateral labyrinthectomy or vestibular afferent activity blockade by transtympanic tetrodotoxin injection in the rat. Neuroscience 2005 130 4 853 865 10.1016/j.neuroscience.2004.08.052 15652984
108 Waele C. Torres A.C. Josset P. Vidal P.P. Evidence for reactive astrocytes in rat vestibular and cochlear nuclei following unilateral inner ear lesion. Eur. J. Neurosci. 1996 8 9 2006 2018 10.1111/j.1460-9568.1996.tb01344.x 8921291
109 Liberge M. Manrique C. Bernard-Demanze L. Lacour M. Changes in TNFα, NFκB and MnSOD protein in the vestibular nuclei after unilateral vestibular deafferentation. J. Neuroinflammation 2010 7 1 91 10.1186/1742-2094-7-91 21143912
110 Vignaux G. Chabbert C. Gaboyard-Niay S. Travo C. Machado M.L. Denise P. Comoz F. Hitier M. Landemore G. Philoxène B. Besnard S. Evaluation of the chemical model of vestibular lesions induced by arsanilate in rats. Toxicol. Appl. Pharmacol. 2012 258 1 61 71 10.1016/j.taap.2011.10.008 22023963
111 Zwergal A. Günther L. Brendel M. 2017 https://www.frontiersin.org/article/10.3389/fneur.2017.00665
112 Flook M. Frejo L. Gallego-Martinez A. Martin-Sanz E. Rossi-Izquierdo M. Amor-Dorado J.C. Soto-Varela A. Santos-Perez S. Batuecas-Caletrio A. Espinosa-Sanchez J.M. Pérez-Carpena P. Martinez-Martinez M. Aran I. Lopez-Escamez J.A. Differential proinflammatory signature in vestibular migraine and meniere disease. Front. Immunol. 2019 10 1229 10.3389/fimmu.2019.01229 31214186
113 Karve I.P. Taylor J.M. Crack P.J. The contribution of astrocytes and microglia to traumatic brain injury. Br. J. Pharmacol. 2016 173 4 692 702 10.1111/bph.13125 25752446
114 Dong H. Zhang W. Zeng X. Hu G. Zhang H. He S. Zhang S. Histamine induces upregulated expression of histamine receptors and increases release of inflammatory mediators from microglia. Mol. Neurobiol. 2014 49 3 1487 1500 10.1007/s12035-014-8697-6 24752587
115 Xu J. Zhang X. Qian Q. Wang Y. Dong H. Li N. Qian Y. Jin W. Histamine upregulates the expression of histamine receptors and increases the neuroprotective effect of astrocytes. J. Neuroinflammation 2018 15 1 41 10.1186/s12974-018-1068-x 29433511
116 Frick L. Rapanelli M. Abbasi E. Ohtsu H. Pittenger C. Histamine regulation of microglia: Gene-environment interaction in the regulation of central nervous system inflammation. Brain Behav. Immun. 2016 57 326 337 10.1016/j.bbi.2016.07.002 27381299
117 Barata-Antunes S. Cristóvão A.C. Pires J. Rocha S.M. Bernardino L. Dual role of histamine on microglia-induced neurodegeneration. Biochim. Biophys. Acta Mol. Basis Dis. 2017 1863 3 764 769 10.1016/j.bbadis.2016.12.016 28057587
118 Ferreira R. Santos T. Gonçalves J. Baltazar G. Ferreira L. Agasse F. Bernardino L. Histamine modulates microglia function. J. Neuroinflammation 2012 9 1 90 10.1186/1742-2094-9-90 22569158
119 Lenz K.M. Pickett L.A. Wright C.L. Davis K.T. Joshi A. McCarthy M.M. Mast cells in the developing brain determine adult sexual behavior. J. Neurosci. 2018 38 37 8044 8059 10.1523/JNEUROSCI.1176-18.2018 30093566
120 Rocha S.M. Saraiva T. Cristóvão A.C. Ferreira R. Santos T. Esteves M. Saraiva C. Je G. Cortes L. Valero J. Alves G. Klibanov A. Kim Y.S. Bernardino L. Histamine induces microglia activation and dopaminergic neuronal toxicity via H1 receptor activation. J. Neuroinflammation 2016 13 1 137 10.1186/s12974-016-0600-0 27260166
121 Zhang W. Zhang X. Zhang Y. Qu C. Zhou X. Zhang S. Histamine induces microglia activation and the release of proinflammatory mediators in rat brain via H1R or H4R. J. Neuroimmune Pharmacol. 2020 15 2 280 291 10.1007/s11481-019-09887-6 31863333
122 Zhu J. Qu C. Lu X. Zhang S. Activation of microglia by histamine and substance P. Cell. Physiol. Biochem. 2014 34 3 768 780 10.1159/000363041 25170632
123 Rocha S.M. Pires J. Esteves M. Histamine: A new immunomodulatory player in the neuron-glia crosstalk. Front Cell Neurosci. 2014 8 120 Available from: https://www.frontiersin.org/article/10.3389/fncel.2014.00120 (2014, accessed 17 January 2022). 10.3389/fncel.2014.00120 24817841
124 Elenkov I.J. Webster E. Papanicolaou D.A. Fleisher T.A. Chrousos G.P. Wilder R.L. Histamine potently suppresses human IL-12 and stimulates IL-10 production via H2 receptors. J. Immunol. 1998 161 5 2586 2593 10.4049/jimmunol.161.5.2586 9725260
125 Mazzoni A. Young H.A. Spitzer J.H. Visintin A. Segal D.M. Histamine regulates cytokine production in maturing dendritic cells, resulting in altered T cell polarization. J. Clin. Invest. 2001 108 12 1865 1873 10.1172/JCI200113930 11748270
126 Morichika T. Takahashi H.K. Iwagaki H. Yoshino T. Tamura R. Yokoyama M. Mori S. Akagi T. Nishibori M. Tanaka N. Histamine inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production in an intercellular adhesion molecule-1- and B7.1-dependent manner. J. Pharmacol. Exp. Ther. 2003 304 2 624 633 10.1124/jpet.102.042515 12538815
127 Takahashi H.K. Morichika T. Iwagaki H. Tamura R. Kubo S. Yoshino T. Mori S. Akagi T. Tanaka N. Nishibori M. Histamine downregulates CD14 expression via H2 receptorson human monocytes. Clin. Immunol. 2003 108 3 274 281 10.1016/S1521-6616(03)00140-2 14499251
128 Aldinucci A. Bonechi E. Manuelli C. Nosi D. Masini E. Passani M.B. Ballerini C. Histamine regulates actin cytoskeleton in human toll-like receptor 4-activated monocyte-derived dendritic cells tuning CD4+ T lymphocyte response. J. Biol. Chem. 2016 291 28 14803 14814 10.1074/jbc.M116.720680 27226579
129 Iida T. Yoshikawa T. Matsuzawa T. Naganuma F. Nakamura T. Miura Y. Mohsen A.S. Harada R. Iwata R. Yanai K. Histamine H 3 receptor in primary mouse microglia inhibits chemotaxis, phagocytosis, and cytokine secretion. Glia 2015 63 7 1213 1225 10.1002/glia.22812 25754956
130 Li H. Godfrey D.A. Rubin A.M. Astrocyte reaction in the rat vestibular nuclei after unilateral removal of Scarpa’s ganglion. Ann. Otol. Rhinol. Laryngol. 1999 108 2 181 188 10.1177/000348949910800214 10030238
131 El Mahmoudi N. Rastoldo G. Marouane E. Péricat D. Watabe I. Tonetto A. Hautefort C. Chabbert C. Sargolini F. Tighilet B. Breaking a dogma: acute anti-inflammatory treatment alters both post-lesional functional recovery and endogenous adaptive plasticity mechanisms in a rodent model of acute peripheral vestibulopathy. J. Neuroinflammation 2021 18 1 183 10.1186/s12974-021-02222-y 34419105
132 Marouane E. El Mahmoudi N. Rastoldo G. Péricat D. Watabe I. Lapôtre A. Tonetto A. Xavier F. Dumas O. Chabbert C. Artzner V. Tighilet B. Sensorimotor rehabilitation promotes vestibular compensation in a rodent model of acute peripheral vestibulopathy by promoting microgliogenesis in the deafferented vestibular nuclei. Cells 2021 10 12 3377 10.3390/cells10123377 34943885
133 Rastoldo G. Marouane E. El-Mahmoudi N. Péricat D. Watabe I. Lapotre A. Tonetto A. López-Juárez A. El-Ahmadi A. Caron P. Fraysse M.J.E. Chabbert C. Zwergal A. Tighilet B. L-Thyroxine improves vestibular compensation in a rat model of acute peripheral vestibulopathy: Cellular and behavioral aspects. Cells 2022 11 4 684 10.3390/cells11040684 35203333
134 El Mahmoudi N. Marouane E. Rastoldo G. Pericat D. Watabe I. Lapotre A. Tonetto A. Chabbert C. Tighilet B. Microglial dynamics modulate vestibular compensation in a rodent model of vestibulopathy and condition the expression of plasticity mechanisms in the deafferented vestibular nuclei. Cells 2022 11 17 2693 10.3390/cells11172693 36078101
135 Wang J. Liu B. Sun F. Xu Y. Luan H. Yang M. Wang C. Zhang T. Zhou Z. Yan H. Histamine H3R antagonist counteracts the impaired hippocampal neurogenesis in Lipopolysaccharide-induced neuroinflammation. Int. Immunopharmacol. 2022 110 109045 10.1016/j.intimp.2022.109045 35978505
136 Saraiva C. Barata-Antunes S. Santos T. Ferreiro E. Cristóvão A.C. Serra-Almeida C. Ferreira R. Bernardino L. Histamine modulates hippocampal inflammation and neurogenesis in adult mice. Sci. Rep. 2019 9 1 8384 10.1038/s41598-019-44816-w 31182747
137 Frejo L. Lopez-Escamez J.A. Cytokines and inflammation in meniere disease. Clin. Exp. Otorhinolaryngol. 2022 15 1 49 59 10.21053/ceo.2021.00920 35124944
138 Chabbert C. Principles of vestibular pharmacotherapy. Handb. Clin. Neurol. 2016 137 207 218 27638072
139 Zwergal A. Strupp M. Brandt T. Advances in pharmacotherapy of vestibular and ocular motor disorders. Expert Opin. Pharmacother. 2019 20 10 1267 1276 10.1080/14656566.2019.1610386 31030580
140 Lacour M. Sterkers O. Histamine and betahistine in the treatment of vertigo: Elucidation of mechanisms of action. CNS Drugs 2001 15 11 853 870 10.2165/00023210-200115110-00004 11700150
141 Lin E. Aligene K. Pharmacology of balance and dizziness. NeuroRehabilitation 2013 32 3 529 542 10.3233/NRE-130875 23648607
142 Soto E. Vega R. Seseña E. Neuropharmacological basis of vestibular system disorder treatment. J. Vestib. Res. 2013 23 3 119 137 10.3233/VES-130494 24177345
143 Venail F. Attali P. Wersinger E. Gomeni R. Poli S. Schmerber S. Safety, tolerability, pharmacokinetics and pharmacokinetic‐pharmacodynamic modelling of the novel H 4 receptor inhibitor SENS‐111 using a modified caloric test in healthy subjects. Br. J. Clin. Pharmacol. 2018 84 12 2836 2848 10.1111/bcp.13744 30152527
144 Fermin H. Van Deinse J.B. Hammelburg E. The effect of dimenhydrinate upon the labyrinth; (an experimental study). Acta Otolaryngol. 1950 38 6 543 549 10.3109/00016485009118417 14856685
145 Halpert A. Olmstead M.C. Beninger R.J. Mechanisms and abuse liability of the anti-histamine dimenhydrinate. Neurosci. Biobehav. Rev. 2002 26 1 61 67 10.1016/S0149-7634(01)00038-0 11835984
146 Jaju B.P. Wang S.C. Effects of diphenhydramine and dimenhydrinate on vestibular neuronal activity of cat: A search for the locus of their antimotion sickness action. J. Pharmacol. Exp. Ther. 1971 176 3 718 724 4329456
147 Kirtane M.V. Bhandari A. Narang P. Santani R. Cinnarizine: A contemporary review. Indian J. Otolaryngol. Head Neck Surg. 2019 71 S2 1060 1068 10.1007/s12070-017-1120-7 31750127
148 Mangabeira-Albernaz P.L. Ganança M.M. Novo N.F. de Paiva E.R. Flunarizine and cinnarizine as vestibular depressants. A statistical study. ORL J. Otorhinolaryngol. Relat. Spec. 1978 40 2 92 100 10.1159/000275391 311458
149 Haasler T. Homann G. Duong D.T.A. Jüngling E. Westhofen M. Lückhoff A. Pharmacological modulation of transmitter release by inhibition of pressure-dependent potassium currents in vestibular hair cells. Naunyn Schmiedebergs Arch. Pharmacol. 2009 380 6 531 538 10.1007/s00210-009-0463-3 19830405
150 Overstall P.W. Hazell J.W.P. Johnson A.L. Vertigo in the elderly. Age Ageing 1981 10 2 105 109 10.1093/ageing/10.2.105 7246334
151 Ehlert F.J. Yamamura H.I. A comparison of the effects of cinnarizine and related compounds on [3H]nitrendipine binding in the brain, heart and ileum. Life Sci. 1984 34 24 2347 2355 10.1016/0024-3205(84)90421-1 6328164
152 Fujimoto S. Sasa M. Takaori S. Matsuoka I. Selective effect of cinnarizine on the vestibular nucleus neurons. Arch. Otorhinolaryngol. 1978 221 1 37 45 10.1007/BF00456382 697647
153 Hahn A. Novotný M. Shotekov P.M. Cirek Z. Bognar-Steinberg I. Baumann W. Comparison of cinnarizine/dimenhy-drinate fixed combination with the respective monotherapies for vertigo of various origins: A randomized, double-blind, active-controlled, multicentre study. Clin. Drug Investig. 2011 31 6 371 383 10.2165/11588920-000000000-00000 21401214
154 Scholtz A.W. Ilgner J. Loader B. Pritschow B.W. Weisshaar G. Cinnarizine and dimenhydrinate in the treatment of vertigo in medical practice. Wien. Klin. Wochenschr. 2016 128 9-10 341 347 10.1007/s00508-015-0905-5 26659910
155 Plescia F. Salvago P. Dispenza F. Messina G. Cannizzaro E. Martines F. Efficacy and pharmacological appropriateness of cinnarizine and dimenhydrinate in the treatment of vertigo and related symptoms. Int. J. Environ. Res. Public Health 2021 18 9 4787 10.3390/ijerph18094787 33946152
156 Scholtz A.W. Hahn A. Stefflova B. Medzhidieva D. Ryazantsev S.V. Paschinin A. Kunelskaya N. Schumacher K. Weisshaar G. Efficacy and safety of a fixed combination of cinnarizine 20 mg and dimenhydrinate 40 mg vs betahistine dihydrochloride 16 mg in patients with peripheral vestibular vertigo: A prospective, multinational, multicenter, double-blind, randomized, non-inferiority clinical trial. Clin. Drug Investig. 2019 39 11 1045 1056 10.1007/s40261-019-00858-6 31571128
157 Scholtz A.W. Waldfahrer F. Hampel R. Weisshaar G. Efficacy and safety of a fixed-dose combination of cinnarizine 20 mg and dimenhydrinate 40 mg in the treatment of patients with vestibular vertigo: An individual patient data meta-analysis of randomised, double-blind, controlled clinical trials. Clin. Drug Investig. 2022 42 9 705 720 10.1007/s40261-022-01184-0 35864302
158 Taghdiri F. Togha M. Razeghi J.S. Refaeian F. Cinnarizine for the prophylaxis of migraine associated vertigo: A retrospective study. Springerplus 2014 3 1 231 10.1186/2193-1801-3-231 24834377
159 Teggi R. Colombo B. Gatti O. Comi G. Bussi M. Fixed combination of cinnarizine and dimenhydrinate in the prophylactic therapy of vestibular migraine: An observational study. Neurol. Sci. 2015 36 10 1869 1873 10.1007/s10072-015-2270-6 26037548
160 Corvera J. Corvera-Behar G. Lapilover V. Ysunza A. Objective evaluation of the effect of flunarizine on vestibular neuritis. Otol. Neurotol. 2002 23 6 933 937 10.1097/00129492-200211000-00020 12438858
161 Rashid S.M.U. Sumaria S. Koohi N. Arshad Q. Kaski D. Patient experience of flunarizine for vestibular migraine: Single centre observational study. Brain Sci. 2022 12 4 415 10.3390/brainsci12040415 35447947
162 Yiannakis C. Hamilton L. Slim M. Kontorinis G. A systematic review and meta-analysis of prophylactic medication of vestibular migraine. J. Laryngol. Otol. 2023 137 9 953 961 10.1017/S0022215122001979 36200521
163 Jeck-Thole S. Wagner W. Betahistine. Drug Saf. 2006 29 11 1049 1059 10.2165/00002018-200629110-00004 17061910
164 Murdin L. Hussain K. Schilder A.G. Betahistine for symptoms of vertigo. Cochrane Database Syst. Rev. 2016 2016 6 CD010696 10.1002/14651858.CD010696 27327415
165 Bertlich M. Ihler F. Sharaf K. Weiss B.G. Strupp M. Canis M. Betahistine metabolites, aminoethylpyridine, and hydroxyethylpyridine increase cochlear blood flow in guinea pigs in vivo. Int. J. Audiol. 2014 53 10 753 759 10.3109/14992027.2014.917208 25014609
166 Ihler F. Bertlich M. Sharaf K. Strieth S. Strupp M. Canis M. Betahistine exerts a dose-dependent effect on cochlear stria vascularis blood flow in guinea pigs in vivo. PLoS One 2012 7 6 e39086 10.1371/journal.pone.0039086 22745706
167 Laurikainen E.A. Miller J.M. Quirk W.S. Kallinen J. Ren T. Nuttall A.L. Grénman R. Virolainen E. Betahistine-induced vascular effects in the rat cochlea. Am. J. Otol. 1993 14 1 24 30 8424471
168 Martinez D.M. The effect of Serc (betahistine hydrochloride) on the circulation of the inner ear in experimental animals. Acta Otolaryngol. 1972 74 sup305 29 47 10.3109/00016487209122697 5068757
169 Bertlich M. Ihler F. Freytag S. Weiss B.G. Strupp M. Canis M. Histaminergic H-3-heteroreceptors as a potential mediator of betahistine-induced increase in cochlear blood flow. Audiol. Neurotol. 2015 20 5 283 293 10.1159/000368293 26139562
170 Bertlich M. Ihler F. Weiss B.G. Freytag S. Strupp M. Jakob M. Canis M. Role of capillary pericytes and precapillary arterioles in the vascular mechanism of betahistine in a guinea pig inner ear model. Life Sci. 2017 187 17 21 10.1016/j.lfs.2017.08.015 28818391
171 Dziadziola J.K. Laurikainen E.L. Rachel J.D. Quirk W.S. Betahistine increases vestibular blood flow. Otolaryngol. Head Neck Surg. 1999 120 3 400 405 10.1016/S0194-5998(99)70283-4 10064646
172 Laurikainen E. Miller J.M. Quirk W.S. Nuttall A.L. The vascular mechanism of action of betahistine in the inner ear of the guinea pig. Eur. Arch. Otorhinolaryngol. 1998 255 3 119 123 10.1007/s004050050025 9561856
173 Dyhrfjeld-Johnsen J. Attali P. Management of peripheral vertigo with antihistamines: New options on the horizon. Br. J. Clin. Pharmacol. 2019 85 10 2255 2263 10.1111/bcp.14046 31269270
174 Adrion C. Fischer C.S. Wagner J. Gürkov R. Mansmann U. Strupp M. Efficacy and safety of betahistine treatment in patients with Meniere’s disease: Primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial). BMJ 2016 352 h6816 10.1136/bmj.h6816 26797774
175 Lezius F. Adrion C. Mansmann U. Jahn K. Strupp M. High-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Menière’s disease: a case series. Eur. Arch. Otorhinolaryngol. 2011 268 8 1237 1240 10.1007/s00405-011-1647-2 21626121
176 Liu J.L. Liu J.G. Chen X.B. Liu Y.H. The benefits of betahistine or vestibular rehabilitation (Tetrax biofeedback) on the quality of life and fall risk in patients with Ménière’s disease. J. Laryngol. Otol. 2020 134 12 1073 1076 10.1017/S0022215120002509 33280619
177 Nauta J.J.P. Meta-analysis of clinical studies with betahistine in Ménière’s disease and vestibular vertigo. Eur. Arch. Otorhinolaryngol. 2014 271 5 887 897 10.1007/s00405-013-2596-8 23778722
178 Ramos A.R. Ledezma R.J.G. Navas R. A.; Cardenas Nuñez, J.L.; Rodríguez, M.V.; Deschamps, J.J.; Liviac, T.J.A. Use of betahistine in the treatment of peripheral vertigo. Acta Otolaryngol. 2015 135 12 1205 1211 10.3109/00016489.2015.1072873 26245698
179 Sanchez-Vanegas G. Castro-Moreno C. Buitrago D. Betahistine in the treatment of peripheral vestibular vertigo: Results of a real-life study in primary care. Ear Nose Throat J. 2020 99 6 356 360 10.1177/0145561319849946 31111729
180 Van Esch B. van der Zaag-Loonen H. Bruintjes T. van Benthem P.P. Betahistine in ménière’s disease or syndrome: A systematic review. Audiol. Neurotol. 2022 27 1 1 33 10.1159/000515821 34233329
181 Tighilet B. Leonard J. Lacour M. Betahistine dihydrochloride treatment facilitates vestibular compensation in the cat. J. Vestib. Res. 1995 5 1 53 66 10.3233/VES-1995-5106 7711948
182 Fukuda J. Matsuda K. Sato G. Kitahara T. Matsuoka M. Azuma T. Kitamura Y. Tomita K. Takeda N. Effects of betahistine on the development of vestibular compensation after unilateral labyrinthectomy in rats. Brain Sci. 2021 11 3 360 10.3390/brainsci11030360 33799856
183 Zhang Y.X. Wang H.X. Li Q.X. Chen A.X. Wang X.X. Zhou S. Xie S.T. Li H.Z. Wang J.J. Zhang Q. Zhang X.Y. Zhu J.N. A comparative study of vestibular improvement and gastrointestinal effect of betahistine and gastrodin in mice. Biomed. Pharmacother. 2022 153 113344 10.1016/j.biopha.2022.113344 35780620
184 Tian C.J. Kim S.W. Kim Y.J. Lim H.J. Park R. So H.S. Choung Y.H. Red ginseng protects against gentamicin-induced balance dysfunction and hearing loss in rats through antiapoptotic functions of ginsenoside Rb1. Food Chem. Toxicol. 2013 60 369 376 10.1016/j.fct.2013.07.069 23933362
185 Tighilet B. Trico J. Xavier F. Chabbert C. What predictability for animal models of peripheral vestibular disorders? Biomedicines 2022 10 12 3097 10.3390/biomedicines10123097 36551852
186 Eisenman D.J. Speers R. Telian S.A. Labyrinthectomy versus vestibular neurectomy: Long-term physiologic and clinical outcomes. Otol. Neurotol. 2001 22 4 539 548 10.1097/00129492-200107000-00022 11449114
187 Hoffmann K.K. Silverstein H. Inner ear perfusion: Indications and applications. Curr. Opin. Otolaryngol. Head Neck Surg. 2003 11 5 334 339 10.1097/00020840-200310000-00005 14502063
188 Sargent E.W. Liao E. Gonda R.L. Jr Cochlear patency after transmastoid labyrinthectomy for ménière’s syndrome. Otol. Neurotol. 2016 37 7 937 939 10.1097/MAO.0000000000001105 27300724
189 Van de Heyning P. Betka J. Chovanec M. Devèze A. Giannuzzi A.L. Krempaská S. Przewoźny T. Scheich M. Strupp M. Van Rompaey V. Meyer T. Efficacy and safety of intranasal betahistine in the treatment of surgery-induced acute vestibular syndrome: a double-blind, randomized, placebo-controlled phase 2 Study. Otol. Neurotol. 2023 44 5 493 501 10.1097/MAO.0000000000003856 37026797
190 Arrang J.M. Garbarg M. Schwartz J.C. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983 302 5911 832 837 10.1038/302832a0 6188956
191 Arrang J.M. Garbarg M. Schwartz J.C. Autoregulation of histamine release in brain by presynaptic H3-receptors. Neuroscience 1985 15 2 553 562 10.1016/0306-4522(85)90233-7 4022339
192 Arrang J-M. Garbarg M. Schwartz J-C. Autoinhibition of histamine synthesis mediated by presynaptic H3-receptors. Neuroscience 1987 23 1 149 157 10.1016/0306-4522(87)90279-X 2446202
193 Schwartz J.C. Arrang J.M. Garbarg M. Gulat-Marnay C. Pollard H. Modulation of histamine synthesis and release in brain via presynaptic autoreceptors and heteroreceptors. Ann. N. Y. Acad. Sci. 1990 604 1 40 54 10.1111/j.1749-6632.1990.tb31981.x 1699464
194 Bergquist F. Ruthven A. Ludwig M. Dutia M.B. Histaminergic and glycinergic modulation of GABA release in the vestibular nuclei of normal and labyrinthectomised rats. J. Physiol. 2006 577 3 857 868 10.1113/jphysiol.2006.120493 17038426
195 Bergquist F. Dutia M.B. Central histaminergic modulation of vestibular function - a review. Sheng Li Xue Bao 2006 58 4 293 304 16906328
196 Tighilet B. Trottier S. Lacour M. Dose- and duration-dependent effects of betahistine dihydrochloride treatment on histamine turnover in the cat. Eur. J. Pharmacol. 2005 523 1-3 54 63 10.1016/j.ejphar.2005.09.017 16226741
197 Chávez H. Vega R. Valli P. Mira E. Benvenuti C. Guth P.S. Soto E. Action mechanism of betahistine in the vestibular end organs. Acta Otorhinolaryngol. Ital. 2001 21 3 Suppl. 66 8 15 11677837
198 Soto E. Chávez H. Valli P. Benvenuti C. Vega R. Betahistine produces post-synaptic inhibition of the excitability of the primary afferent neurons in the vestibular endorgans. Acta Otolaryngol. Suppl. 2001 545 19 24 11677735
199 Bellot-Saez A. Kékesi O. Morley J.W. Buskila Y. Astrocytic modulation of neuronal excitability through K + spatial buffering. Neurosci. Biobehav. Rev. 2017 77 87 97 10.1016/j.neubiorev.2017.03.002 28279812
200 Losi G. Mariotti L. Sessolo M. Carmignoto G. New tools to study astrocyte ca2+ signal dynamics in brain networks in vivo. Front. Cell. Neurosci. 2017 11 134 10.3389/fncel.2017.00134 28536505
201 Jurič D.M. Kržan M. Lipnik-Stangelj M. Histamine and astrocyte function. Pharmacol. Res. 2016 111 774 783 10.1016/j.phrs.2016.07.035 27475882
202 Kárpáti A. Yoshikawa T. Nakamura T. Iida T. Matsuzawa T. Kitano H. Harada R. Yanai K. Histamine elicits glutamate release from cultured astrocytes. J. Pharmacol. Sci. 2018 137 2 122 128 10.1016/j.jphs.2018.05.002 29858014
203 Fang Q. Hu W.W. Wang X.F. Yang Y. Lou G.D. Jin M.M. Yan H.J. Zeng W.Z. Shen Y. Zhang S.H. Xu T.L. Chen Z. Histamine up-regulates astrocytic glutamate transporter 1 and protects neurons against ischemic injury. Neuropharmacology 2014 77 156 166 10.1016/j.neuropharm.2013.06.012 23791559
204 Ferrini F. De Koninck Y. Microglia control neuronal network excitability via BDNF signalling. Neural Plast. 2013 2013 1 11 10.1155/2013/429815 24089642
205 Hagemeyer N. Hanft K.M. Akriditou M.A. Unger N. Park E.S. Stanley E.R. Staszewski O. Dimou L. Prinz M. Microglia contribute to normal myelinogenesis and to oligodendrocyte progenitor maintenance during adulthood. Acta Neuropathol. 2017 134 3 441 458 10.1007/s00401-017-1747-1 28685323
206 Botta L. Mira E. Valli S. Zucca G. Perin P. Benvenuti C. Fossati A. Valli P. Effects of betahistine metabolites on frog ampullar receptors. Acta Otolaryngol. 2000 120 1 25 27 10.1080/000164800760370783 10779181
207 Qin D. Zhang H. Wang J. Hong Z. Histamine H4 receptor gene polymorphisms: a potential contributor to Meniere disease. BMC Med. Genomics 2019 12 1 71 10.1186/s12920-019-0533-4 31133025
208 Zampeli E. Tiligada E. The role of histamine H 4 receptor in immune and inflammatory disorders. Br. J. Pharmacol. 2009 157 1 24 33 10.1111/j.1476-5381.2009.00151.x 19309354
209 Gazquez I. Soto-Varela A. Aran I. Santos S. Batuecas A. Trinidad G. Perez-Garrigues H. Gonzalez-Oller C. Acosta L. Lopez-Escamez J.A. High prevalence of systemic autoimmune diseases in patients with Menière’s disease. PLoS One 2011 6 10 e26759 10.1371/journal.pone.0026759 22053211
210 Zhou P. Homberg J.R. Fang Q. Wang J. Li W. Meng X. Shen J. Luan Y. Liao P. Swaab D.F. Shan L. Liu C. Histamine-4 receptor antagonist JNJ7777120 inhibits pro-inflammatory microglia and prevents the progression of Parkinson-like pathology and behaviour in a rat model. Brain Behav. Immun. 2019 76 61 73 10.1016/j.bbi.2018.11.006 30408497
